Journal articles: '579.307 2'

1

Cunningham-Smith, K. A., R. Witherdin, L. Hetherington, M. A. Baker, and R. Aitken. "277.The role of pp60c-src tyrosine kinase in sperm capacitation." Reproduction, Fertility and Development 16, no. 9 (2004): 277. http://dx.doi.org/10.1071/srb04abs277.

Full text

Abstract:

A protein kinase A-dependent tyrosine phosphorylation pathway in mammalian spermatozoa has been demonstrated to exist, and is unique to this cell type. As PKA is incapable of directly phosphorylating substrates on tyrosine residues, much research has focused on the identification of an intermediary tyrosine kinase which can be activated by serine/threonine phosphorylation via PKA. Inhibitory studies using genistein, tryphostin, erbstatin and herbimycin A, have demonstrated that the src family of kinases may be responsible for the tyrosine phosphorylation events seen during capacitation (1). Although one src family member, c-yes, has been implicated as the kinase responsible for these events (2), this has since been disputed (3). Another src family member, pp60c-src, can be activated by phosphorylation on Ser-17 by cAMP-dependent protein kinase and Ser-12 by calcium-phospholipid dependent protein kinase C (4), and may be the intermediary tyrosine kinase of interest. Western blot analysis demonstrated the presence of pp60c-src in rat sperm samples isolated from the caput and cauda epididymis. Furthermore, co-immunoprecipitation studies revealed a number of pp60c-src-associated proteins including outer dense fibre 2 (ODF2) and A-kinase anchoring protein 4 (AKAP4). Interestingly, both of these proteins become phosphorylated during capacitation of mouse sperm (data not shown) and AKAP4 is tyrosine phosphorylated in capacitated human sperm (5). These data implicate pp60c-src kinase activity in the phosphorylation of a number of sperm midpiece proteins, which may regulate hyperactivation during capacitation. Further research focusing on the activity of pp60c-src in non-capacitated and capacitated sperm will be conducted. (1) Yaciuk P., et al. (1989) Mol. Cell Biol. 9, 2453–2461. (2) Baker M., et al. (2003) J. Cell Sci. 117, 211–222. (3) Leclerc P., Goupil S (2002) Biol. Reprod. 67, 301–307. (4) Bajpai M., et al. (2003) Arch. Androl. 49, 229–246. (5) Ficarro S., et al. (2003) J. Biol. Chem. 278, 11�579–11�589.

APA, Harvard, Vancouver, ISO, and other styles

2

Kraggerud, Egil. "Further Textual Issues in theAeneid(2. 749; 5. 300; 9. 539)." Symbolae Osloenses 86, no. 1 (October 2012): 102–10. http://dx.doi.org/10.1080/00397679.2012.691357.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Maulana, Ucup, Fauziah Fauziah, and Ira Diana Sholihati. "Forward Chaining Algorithm and Simple Additive Weighting (SAW) in Smart HelpDesk Ticketing Information System." CESS (Journal of Computer Engineering, System and Science) 7, no. 1 (January 17, 2022): 195. http://dx.doi.org/10.24114/cess.v7i1.29750.

Full text

Abstract:

Tujuan dari penelitian ini adalah menjadi solusi membantu tim helpdesk dalam mengelola proses dari membuat tiket hingga penyelesaiannya. Penelitian ini menggunakan algoritma kombinasi Forward Chaining untuk mengelola SLA (Service Level Agreement) pengerjaan tiket dan Simple Additive Weighting (SAW) untuk prioritas pengerjaan tiket. Pengujian telah dilakukan sebanyak 600 data, metode forward chaining mencatat SLA pengerjaan tiket seperti urutan 1 sampai 20 berdurasi 7.9 jam indikator warna hijau, 21 sampai 40 durasi 6 jam berindikator kuning, 41 sampai 70 berdurasi 3 jam indikator hijau, 71 sampai 172 berdurasi 7 hari 19 jam indikator merah, 173 sampai 174 durasi 4 hari, 175 sampai 230 durasi 2 hari 21 jam, 231 sampai 260 berdurasi 8 jam berwarna kuning, 261 sampai 305 4 jam berwarna hijau, 306 sampai 325 berdurasi 7 hari 19 jam indikator merah, 326 sampai 345 berdurasi 12.6 jam berwarna kuning, 346 sampai 356 berdurasi 6.5 jam warna hijau, 357 sampai 469 berdurasi 7 hari 19 jam indikator merah, 470 sampai 475 berdurasi 4 hari, 476 sampai 556 berdurasi 2 hari 19 jam indikator merah, 557 sampai 576 berdurasi 23.9 jam berwarna kuning dan 577 sampai 600 berdurasi 7 jam serta berwarna hijau. Metode SAW mengurutkan prioritas pengerjaan berdasarkan bobot dan nilai awal yang telah ditentukan. Urutan 1 sampai 70 bernilai 100 diperingkat kesatu, 71 sampai 305 bernilai 55 diperingkat kedua, 306 sampai 356 dengan nilai 25 diperingkat ketiga, dan 357 sampai 600 bernilai 10 serta diperingkat keempat.

APA, Harvard, Vancouver, ISO, and other styles

4

Yuasa, Mitsuhiro, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, et al. "Low Lymphocyte Count at Day 30 after Single Cord Blood Transplantation Had Negative Impact on Survival, Because of Higher NRM Rate." Blood 134, Supplement_1 (November 13, 2019): 4482. http://dx.doi.org/10.1182/blood-2019-130662.

Full text

Abstract:

<Introduction> Delayed immune reconstitution after allogeneic transplantation increases the risk of treatment-related mortality, and chronic GVHD. Previous reports showed that absolute lymphocyte count at day 30 (ALC30) was a significant prognostic factor of transplantation, and lower numbers of total CD4+ T cells and naïve CD4+ T cells in particular were associated significantly with higher mortality. However, there is little knowledge about the factors associated with low lymphocyte recovery, especially in cord blood transplantation (CBT). The cut-off value of lymphocyte recovery for statistical significance has not been determined yet. <Methods> We retrospectively analyzed the outcome of 579 consecutive patients who underwent single cord blood transplantation (CBT) for the first time at Toranomon Hospital between January 2011 and 2018. Patients with active infection at transplantation (n=40), in poor ECOG PS (3 or more) (n=36), or lacked information about CT before CBT (n=1) were excluded from this study. <Results> Five hundred and two patients (n=317 male; n=185 female) were included in this study. The median age at transplantation was 57 years (range, 16-77), with a median HCT-CI score of 2 (0-10). Underlying diseases were AML (307), MDS (43), MPN (20), ALL (50), mature lymphoid malignancies (54), and others (28). Median spleen index (SI) before transplantation was 60.2 (16.5-319.7). Three hundred and ninety eight patients (79%) were not in remission at transplant. MAC regimens were selected in 400 (80%). TAC alone was used in 132 (26%) as GVHD prophylaxis. Median number of TNC and CD34+ cells infused were 2.62 (1.57-6.85) x 107/kg and 0.86 (0.29-3.77) x 105/kg, respectively. 194 (39%) were positive for anti-HLA antibodies, but none had donor-specific. With a median follow-up of 32 (range, 3-99) months, cumulative incidence of neutrophil engraftment (NE), the 3-year probabilities of overall survival (OS), relapse rate (RR) and non-relapse mortality (NRM) for entire population were 92.8%, 40.6%, 23.5%, and 35.3%, respectively. Underlying disease (myeloid malignancy), disease status at SCT (non-CR), poor PS (PS=2), GVHD prophylaxis (TAC+MMF), low CD34-positive cell dose (<0.8 x 105/kg), and splenomegary (SI ≥ 40) were significantly associated with inferior NE in multivariate analysis. Disease status at SCT (non-CR), poor PS (PS=2), Higher HCT-CI (PS ≥ 3), and GVHD prophylaxis (TAC+MMF) were significantly associated with higher NRM in multivariate analysis. We analyzed the relationship between ALC30 and transplantation outcome. Median number of ALC30 was 231 (3.5-1503), and the 25th percentile was 144. We divided the cohort into two groups, ALC30 low group (<150, n=123), ALC30 high group (≥150, n=346). High number of ALC30 (≥150) was associated with better survival (48.1% vs. 29.5%, p < 0.01) and lower NRM (26.9% vs. 41.9%, p < 0.01) due to reduced incidence of lethal infection (7.1% and 23.4% of total death in ALC30 high and low, respectively, p < 0.01), but was not associated with RR (25.5% vs. 25.1%, p = 0.59). High ALC30 (≥150), as well as younger age (<60), underlying disease (myeloid malignancy), better PS (0-1), and disease status at SCT (CR) showed a superior OS in multivariate analysis. We then assessed factors associated with ALC30, and higher infused dose of CD34-positive cells was the only factor associated with high ALC30, (p=0.03, t-test). Other factors, such as infused TNC dose, type of conditioning, or GVHD prophylaxis did not show significant association with ALC30. <Conclusion> This retrospective study demonstrated that low ALC30 after CBT had negative impact on survival because of higher NRM rate. High CD34-positive cell dose was the only factor associated with high ALC30. Not CD34-positive cell dose, but ALC30 had significant impact on OS in multivariate analysis, so we need to take lymphocyte recovery into account, in an attempt to improve transplantation outcome. Figure Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

5

Tatte, S. P., N. S. Dhoble, G. C. Mishra, and S. J. Dhoble. "Synthesis characterization and Luminescence Properties of B₂BiMg₂V₃O₁₂ based phosphors with rare earth activated Dy³⁺ phosphor for solid state lighting." IOP Conference Series: Materials Science and Engineering 1258, no. 1 (October 1, 2022): 012016. http://dx.doi.org/10.1088/1757-899x/1258/1/012016.

Full text

Abstract:

Highly new efficient vanadate based phosphor B2BiMg2V3O12 (B= K & Na) material incapacitated through rare-earth Dysprosium (Dy) and it was characterized by high temperature solid-state synthesis. Equipped phosphor was established by X-ray diffraction method. In Photo-luminescence measurements shows that the prepared phosphors doped by Dy is excited by near UV ultraviolet light reaching after 300 nm to 380 nm efficiently acceptable to recognize the emission in visible spectrum (in the range 400 nm –570 nm. The highly efficient prepared phosphor doped with lanthanide doped with Dy phosphor likewise showed the exact emission point at 487 nm and 571 nm at the excitation point at 325 nm. Hence, these prepared phosphors can find numerous applications as green emitting phosphor in the field of solid-state lighting area.

APA, Harvard, Vancouver, ISO, and other styles

6

Rodrigues, Ariana Larissa de Moura, Ana Carolina de Sá Gomes Cruz Souza, Jéssica Gomes Alcoforado de Melo, and Diego Moura Soares. "Lesões em áreas de furca: fatores etiológicos, diagnóstico e tratamento." ARCHIVES OF HEALTH INVESTIGATION 9, no. 6 (December 20, 2020): 635–40. http://dx.doi.org/10.21270/archi.v9i6.5110.

Full text

Abstract:

As lesões de furca ocorrem quando a doença periodontal atinge a área de bifurcação dos dentes multirradiculares causando a destruição óssea e perda de inserção no espaço inter-radicular. Existem diversos fatores etiológicos que influenciam no aparecimento dessas lesões e até os dias de hoje o tratamento desse tipo de injúria ainda é um desafio na clínica odontológica. O objetivo deste artigo foi listar, através de uma revisão da literatura, os fatores que influenciam na etiologia da lesão de furca, bem como o seu diagnóstico, prognóstico e tratamento. Fatores como características morfológicas do dente e raiz e deficiência no controle do biofilme, que podem contribuir para o seu aparecimento. Além de diversos tipos de procedimentos e técnicas têm sido propostas para o tratamento das lesões de furca, seja mais ou menos conservadores. Descritores: Defeitos da Furca; Diagnóstico; Doenças Periodontais. Referências Deliberador TM, Nagata MJH, Furlaneto FAC, Messora MR, Bosco AF, Garcia VG et al. Abordagem conservadora no tratamento dos defeitos de furca. RSBO. 2008;5(8):49-55. Silva GP, Sousa Neto AC, Pereira AFV, Alves CMC, Pereira ALA, Serra LLL. Classificação e tratamento das lesões de furca. Rev Ciênc Saúde. 2014;16(2):112-28. Nibali L, Zavattini A, Nagata K, Di Iorio A, Lin GH, Needleman I, et al. Tooth loss in molars with and without furcation involvement - a systematic review and meta-analysis. J Clin Periodontol. 2016;43(2):156-66. Artacho MCI, Arambulo GM. Defectos de furcación. Etiología, diagnóstico y tratamiento. Rev Estomatol Herediana. 2010;20(3):172-78. Pereira SG, Pinho MM, Almeida RF. Regeneração periodontal em lesões de furca–revisão da literatura. Rev port estomatol med dent cir maxilofac. 2012;53(2):123-32. Queiroz LA, Casarian RCV, Daddoub SM, Tatakis DN, Enilson AS, Kumar PS. Furcation Therapy with Enamel Matrix Derivative: Effects on the Subgingival Microbiome. J Periodontol. 2017;88(7):617-25. Vieira TR, Costa FO, Zenóbio EG, Soares RV. Anatomia radicular e suas implicações na terapêutica periodontal. Rev Periodontia 2009;19(1):7-13. Bower RC. Furcation morphology relative to periodontal treatment. Furcation root surface anatomy. J Periodontol. 1979;50(7):366-74. Newman M, Takei H, Klokkevold P, Carranza F. Periodontia clínica. ed. São Paulo: Elservier; 2016. Lindhe J, Karring T, Lang NP. Tratado de periodontia clínica e implantodontia oral. ed; Rio de Janeiro: Guanabara Koogan;2010. Hamp SE, Nyman S, Lindhe J. Periodontal treatment of multirroted teeth. Result after 5 years. J Clin Periodontol. 1975;2(3):126-35. Ramjford SP, Ash MM. Periodontology and Periodontics. Philadelphia: W.B. Saunders Co; 1979. Tarnow D, Fletcher P. Classification of the vertical component of furcation involvement. J Periodontol. 1984;55(5):283-84. Walter C, Weiger R, Zitman NU. Periodontal surgery in furcation-involved maxillary molars revisited: an introduction of guidelines for comprehensive treatment. Clin Oral Investig. 2011;15(1):9-20. Sallum AW, Cicareli AJ, Querido MRM, Bastos-Neto FVR. Periodontia e implantodontia - Soluções estéticas e recursos clínicos. Rio de Janeiro: Napoleão; 2010. Graziani F, Gennai S, Karapetsa D, Rosini S, Filice N, Gabriele M, et al. Clinical performance of access flap in the treatment of class II furcation defects. A systematic review and meta-analysis of randomized clinical trials. J Clin Periodontol. 2015;42(2):169-81. Svärdström G, Wennström JL. Periodontal treatment decisions for molars: an analysis of influencing factors and long-term outcome. J Periodontol. 2000;71(4):579-85. Huynh-Ba G, Kuonen P, Hofer D, Schmid J, Lang NP, Salvi GE. The effect of periodontal therapy on the survival rate and incidence of complications of multirooted teeth with furcation involvement after an observation period of at least 5 years: a systematic review. J Clin Periodontol. 2009;36(2):164-76. Shirakata Y, Miron RJ, Nakamura T, Sena K, Shinohara Y, Horai N et al. Effects of EMD liquid (Osteogain) on periodontal healing in class III furcation defects in monkeys. J Clin Periodontol. 2017;44(3):298-307. Meyle J, Gonzales JR, Bödeker RH, Hoffmann T, Richter S, Heinz B et al. A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part II: secondary outcomes. J Periodontol. 2004; 75(9):1188-95. Jenabian N, Haghanifar S, Ehsani H, Zahedi E, Haghpanah M. Guided tissue regeneration and platelet rich growth factor for the treatment of Grade II furcation defects: A randomized double-blinded clinical trial - A pilot study. Dent Res J (Isfahan). 2017;14(6):363-69. Kinaia M, Steiger J, Neely AL, Shah M, Bhola M. Treatment of class II molar furcation involvement: meta-analyses of re-entry results. J Periodontol. 2011;82(1):413-28. Correa A, Ferreira PS, Barboza R, Ribeiro EDP, Bittencourt S. Fatores que influenciam no sucesso da técnica do retalho posicionado coronalmente. Rev Bahiana Odonto; 2013;4(2):117-28. Jepsen S, Gennai S, Hirschfeld J, Kalemaj Z, Buti J, Graziani F. Regenerative surgical treatment of furcation defects: A systematic review and Bayesian network meta-analysis of randomized clinical trials. J Clin 2020;47(Suppl 22):352-74. Reddy MS, Aichelmann-Reidy ME, Avila-Ortiz G, Klokkevold PR, Murphy KG, Rosen PS, et al. Periodontal regeneration - furcation defects: a consensus report from the AAP Regeneration J Periodontol. 2015;86(2 Suppl):S131-3. Casarin RCV, Ribeiro EDP, Nociti-Jr FH, Sallum AW, Ambrosano GMB, Sallum EA, et al. Enamel matrix derivative proteins for the treatment of proximal class II furcation involvements: a prospective 24-month randomized clinical trial. J Clin Periodontol; 2010;37(12):1100-109. Hoffmann T, Richter S, Meyle J, Gonzales JR, Heinz B, Arjomand M et al. A randomized clinical multicentre trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part III: patient factors and treatment outcome. J Clin Periodontol. 2006;33(8):575-83.

APA, Harvard, Vancouver, ISO, and other styles

7

Stal, Julia, Kimberly A. Miller, Joel E. Milam, Molly Quinn, Sue E. Kim, Rachel C. Ceasar, and David R. Freyer. "Abstract 2253: Cancer-related follow-up health care utilization and fertility discussion, preservation, and reproductive concerns among diverse adolescent and young adult cancer survivors: A population-based study." Cancer Research 84, no. 6_Supplement (March 22, 2024): 2253. http://dx.doi.org/10.1158/1538-7445.am2024-2253.

Full text

Abstract:

Abstract Purpose: To examine cancer-related follow-up (CRFU) health care utilization associated with fertility experiences among diverse adolescent and young adult (AYA) cancer survivors. Methods: Project Milestones is an ongoing survey study evaluating life outcomes among AYAs diagnosed with cancer at age 21-39 in Los Angeles (LA) County. AYAs had an initial 5-year survival probability of ≥50% and are currently 3-10 years post-diagnosis. A registry-based recruitment strategy through the SEER-affiliated LA Cancer Surveillance Program was used. Results: Overall, 1442 AYAs responded (Table 1). Compared to AYAs who did not, AYAs who saw: (1) their treating provider for CRFU were more likely to report a fertility discussion (56.0% vs. 41.2%, p<.01); (2) another provider for CRFU were less likely to report a fertility discussion (38.1% vs. 52.0%, p<.01); (3) their treating provider for CRFU were more likely to report preserving fertility (14.7% vs. 8.4%, p<.01); (4) a primary care provider for CRFU were less likely to report preserving fertility (10.1% vs. 13.6% p<.05). Compared with AYAs who reported a CRFU visit 1+ years ago or never, AYAs with a visit <1 year ago: (1) had on average greater reproductive concerns (range 5-25, higher scores reflect greater concern, 13.8 vs. 13.4, p<.05); and were more likely to report (2) worry passing on a genetic risk for cancer to their child (55.6% vs. 47.8%, p<.01); and (3) caution about having children because they may not be around to raise them (23.6% vs. 16.6%, p<.01). Discussion: Iatrogenic infertility concerns persistent into survivorship, yielding a need to optimize oncofertility care throughout the reproductive lifespan. Receiving CRFU care from the treating provider is related to better outcomes, and higher reproductive concerns among AYAs with a recent visit may reflect greater awareness of risk due to more points of contact with a provider. Table 1: Sample characteristics - N (%) or M (SD) Total Hispanic Non-Hispanic 1442 622 (43.1) 820 (56.9) Age at survey 39.5 (5.8) 39.3 (5.8) 39.6 (5.7) Female 1007 (69.8) 429 (69.0) 578 (70.5) White 850 (62.4) 301 (55.0) 549 (67.3) Had employee-sponsored insurance 909 (63.0) 347 (55.8) 562 (68.5) Age at diagnosis 31.0 (5.2) 30.8 (5.2) 31.2 (5.1) Cancer type Leukemia/Lymphoma 396 (27.5) 173 (27.8) 223 (27.2) Reproductive 382 (26.5) 208 (33.4) 174 (21.2) Thyroid 184 (12.8) 86 (13.8) 98 (12.0) Breast 179 (12.4) 61 (9.8) 118 (14.4) Skin 130 (9.0) 21 (3.4) 109 (13.3) Colorectal 86 (6.0) 35 (5.6) 51 (6.2) Other 85 (5.9) 38 (6.1) 47 (5.7) Discussed fertility 717 (50.3) 327 (53.4) 390 (48.0) Preserved fertility 176 (12.3) 48 (7.8) 128 (15.7) Reproductive Concerns After Cancer (RCAC) score 14.1 (3.9) 14.3 (4.2) 14.0 (3.8) Last visit with a health care provider for cancer related follow-up care Within the past year 862 (60.3) 343 (56.2) 519 (63.4) 1-2 years ago 218 (15.3) 90 (14.8) 128 (15.6) More than 2 years ago 303 (21.2) 152 (24.9) 151 (18.4) Never 46 (3.2) 25 (4.1) 21 (2.6) Provider seen for cancer related follow-up care Same doctor who treated me 885 (61.4) 369 (59.3) 516 (62.9) Primary care provider 539 (37.4) 224 (36.0) 315 (38.4) Another type of provider 179 (12.4) 65 (10.5) 114 (13.9) Cancer survivorship clinic 88 (6.1) 46 (7.4) 42 (5.1) Citation Format: Julia Stal, Kimberly A. Miller, Joel E. Milam, Molly Quinn, Sue E. Kim, Rachel C. Ceasar, David R. Freyer. Cancer-related follow-up health care utilization and fertility discussion, preservation, and reproductive concerns among diverse adolescent and young adult cancer survivors: A population-based study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2253.

APA, Harvard, Vancouver, ISO, and other styles

8

SEKHAR, M. CHANDRA, B. GOPALA KRISHNA, M. MAHESH KUMAR, and S. V. SURYANARAYANA. "HIGH DIELECTRIC CONSTANT AND NONLINEAR ELECTRIC RESPONSE IN Bi2Sr2SmCu2Oy." Modern Physics Letters B 10, no. 27 (November 20, 1996): 1365–77. http://dx.doi.org/10.1142/s0217984996001541.

Full text

Abstract:

Samples with the nominal composition Bi 2 Sr 2 SmCu 2 O y were prepared by solid state reaction method. From the room temperature X-ray diffraction data, it was found that the sample is similar to the Bi-2212 structure. DC electrical resistivity was done from 80 K to 573 K and the impedance measurements were performed from 80 K to 573 K at different frequencies in the range of 10 kHz to 800 kHz. The sample Bi 2 Sr 2 SmCu 2O y has exhibited semiconducting behavior in the low temperature region (80 K to 343 K), metallic behavior in the temperature range of 343 K to 443 K and again semiconducting behavior above 443 K. The sample has exhibited the phenomenon of variable rangehopping mechanism (VRH). The physical parameters related to VRH such as localization length (a), hopping distance (R) and hopping energy (W) have been evaluated and discussed. The activation energy in the high temperature region (above 300 K) decreases with increasing frequency. Tan δ increases with increase in temperature (303 K-573 K), which is attributed to increased conductivity. The dielectric constant increases with increase in temperature. For a given temperature the value of ε is found to decrease with increase in frequency.

APA, Harvard, Vancouver, ISO, and other styles

9

Ntemgwa, Michel, Mark A. Wainberg, Maureen Oliveira, Daniela Moisi, Richard Lalonde, Valeria Micheli, and Bluma G. Brenner. "Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine." Antimicrobial Agents and Chemotherapy 51, no. 11 (August 27, 2007): 3861–69. http://dx.doi.org/10.1128/aac.00646-07.

Full text

Abstract:

ABSTRACT Mutations in the RNase H domain of human immunodeficiency virus type 1 RT have been reported to cause resistance to zidovudine (ZDV) in vitro. However, very limited data on the in vivo relevance of these mutations in patients exist to date. This study was designed to determine the relationship between mutations in the RNase H domain and viral susceptibility to nucleoside analogues. Viruses harboring complex thymidine analogue mutation (TAM) and nucleoside analogue mutation (NAM) profiles were evaluated for their phenotypic susceptibilities to ZDV, tenofovir (TNF), and the nonapproved nucleoside reverse transcriptase inhibitors (NRTIs) β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (Reverset), β-d-5-fluorodioxolane-cytosine, and apricitabine. As controls, viruses from NRTI-naïve patients were also studied. The pol RT region (codons 21 to 250) of the viruses were sequenced and evaluated for mutations in the RNase H domain (codons 441 to 560) and the connection domain (codons 289 to 400). The results showed that viruses from patients failing multiple NRTI-containing regimens had distinct TAM and NAM profiles that conferred various degrees of resistance to ZDV (0.9- to >300-fold). Sequencing of the RNase H domain identified five positions (positions 460,468, 483, 512, and 519) at which extensive amino acid polymorphisms common in both wild-type viruses and viruses from treated patients were identified. No mutations were observed at positions 539 and 549, which have previously been associated with ZDV resistance. Mutations in the RNase H domain did not appear to correlate with the levels of phenotypic resistance to ZDV. Although some mutations were also observed in the connection domain, the simultaneous presence of the L74V and M184V mutations was the most significant determinant of phenotypic resistance to ZDV in patients infected with viruses with TAMs.

APA, Harvard, Vancouver, ISO, and other styles

10

Keane, M. G., G. J. More O'Ferrall, J. Connolly, and P. Allen. "Carcass composition of serially slaughtered Friesian, Hereford × Friesian and Charolais × Friesian steers finished on two dietary energy levels." Animal Science 50, no. 2 (April 1990): 231–43. http://dx.doi.org/10.1017/s0003356100004682.

Full text

Abstract:

ABSTRACTThe carcass composition of Hereford × Friesian (HE), Friesian (FR) and Charolais × Friesian (CH) steers finished on diets of high (H) and medium (M) dietary metabolizable energy (ME) concentrations and slaughtered at low (L), normal (N) and heavy (W) carcass weights was examined in a 3 × 2 × 3 (no. = 9 per individual treatment) factorial experiment. A pre-finishing slaughter group of nine animals of each breed type was also included, giving a total 189 animals in 21 experimental groups. ME concentrations of the H and M diets which were offered ad libitum were 12·6 and 10·4 MJ/kg dry matter. Target carcass weights for L, N and W were 260, 300 and 340 kg for HE and FR and 260, 320 and 380 kg for CH.Carcass side weights (before tissue separation) of the HE, FR and CH pre-finishing slaughter groups were 90·8, 970 and 101·0 (s.e.d. 3·9) kg. Corresponding tissue proportions were 188, 199 and 200 (s.e.d. 4·3) g/kg bone, 663, 686 and 690 (s.e.d. 5·3) g/kg muscle and 135, 99 and 96 (s.e.d. 5·7) g/kg fat. Main effect side weights of the finished groups were 152·3, 151·4 and 162·2 (s.e.d. 1·4) kg for HE, FR and CH. 158·5 and 152·2 (s.e.d. 1·1) kg for H and M and 131·2, 155·2 and 179·6 (s.e.d. 1·4) kg for L, N and W, respectively. Tissue proportions in the same order were 146, 160 and 157 (s.e.d. 2·0), 149 and 159 (s.e.d. 1·6) and 163, 154 and 146 (s.e.d. 2·0) g/kg bone, 579, 601 and 635 (s.e.d. 5·5), 600 and 610 (s.e.d. 4·5) and 637, 599 and 574 (s.e.d. 5·5) g/kg muscle and 264, 228 and 195 (s.e.d. 6·4), 240 and 219 (s.e.d. 5·2) and 188, 235 and 264 (s.e.d. 6·4) g/kg fat. CH had more (P < 0·001) of their muscle in the pelvic limb and less (P < 0001) in the thorax than HE and FR. HE had more (P < 0·001) of their carcass fat in the subcutaneous depot and less (P < 0·001) in the intermuscular depot than FR and CH. The allometric regression coefficients for the main joint and tissue weights on side weight were <1·0 for both limbs, loin, bone and muscle. Coefficients were >1·0 for the thorax, ribs, flank and fat. The regression coefficients for the main muscles of the pelvic limb and loin and total thoracic limb muscle on total side muscle were <l·0, while the coefficients for the flank, ribs and thorax muscles were >1·0. Similarly the regression coefficients for the bones of the two limbs on total side bone were <10, while the coefficients for the loin, ribs and thorax bones were >10. It was calculated (for the H diet) that at a carcass weight of 300 kg, HE, FR and CH would have carcass tissue proportions of 576, 600 and 642 g/kg muscle and 261, 227 and 180 g/kg fat. The three breed types would have similar carcass fat contents at carcass weights of 264, 300 and 376 kg for HE, FR and CH, respectively.

APA, Harvard, Vancouver, ISO, and other styles

11

Yang, Qi, Xiao-Lei Zhu, Ting-Ting Lu, Jian Ma, Yin Hang, and Wei-Biao Chen. "A 5.9-mJ 500-Hz Electro-Optic Q -Switched 1053 nm Nd:LiLuF 4 Laser." Chinese Physics Letters 31, no. 2 (February 2014): 024205. http://dx.doi.org/10.1088/0256-307x/31/2/024205.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Oganesyan, Oganes G., A. A. Grdikanyan, S. S. Yakovleva, and V. R. Getadaryan. "THE PARTIAL DISCEMETOREXIS WITHOUT TRANSPLANTATION IN CASE OF ENDOTHELIAL DYSTROPHY OF CORNEA." Medical Journal of the Russian Federation 23, no. 6 (December 15, 2017): 302–7. http://dx.doi.org/10.18821/0869-2106-2017-23-6-302-307.

Full text

Abstract:

During the last 20 years, the penetrating keratoplasty gave in its leading place to selective lamellar keratoplasty when pathologically altered layers of cornea are selectively replaced, including endothelium. The main technical task of all procedures of endothelial keratoplasty is an obligatory complete or almost complete post-operative adjacency of endothelial transplant to stroma of recipient. However, there are publications concerning resorption of edema in case of separation of endothelial transplant and even at its absence. The purpose of study. To analyze, on the basis of limited clinical observations, the results of partial discemetorexis (5.25 mm) without transplantation in patients with endothelial dystrophy of cornea (Fuchs).The materials and methods. The study was implemented concerning maximal correcting visual acuity, central thickness of cornea, density of endothelial cells and optical density of cornea, before, in one day, in one week, in 1, 3 and every 6 months after operation. The study covered 6 patients with Fuchs dystrophy (average age 63 ± 6,5 years) operated in 2015-2016 with period of observation neither less than 6 months. The visual acuity before operation in average made up to 0,32 ± 017 mkm, average central thickness of cornea - 677 ± 76 mkm. The native crystalline lens was present in 2 patients. The study was supported by ethical committee of the Helmholtz Moscow research institute of eyes diseases. The results. The resorption of edema of cornea occurred in 2 patients (33%), visual acuity increased from 0.45 to 0.6. In different periods density of endothelial cells varied from 549 to 689 kl/mm2. The central thickness of cornea decreased from 613 ± 33 mkm to 553 ± 15 mkm in 12 months after operation. Conclusion. The discemetorexis (5.25 mm) is more often efficient in case of availability of native crystalline lens, at earlier stages of dystrophy independently of patient's age. The discemetorexis ensures lower indices of maximal correcting visual acuity and density of endothelial cells and higher values of central thickness of cornea in comparison with DMEK. The indices of central thickness of cornea and optical density of cornea are exposed to fluctuations in different periods after discemetorexis (5.25 mm).

APA, Harvard, Vancouver, ISO, and other styles

13

Shavlovskaya, O. A., I. A. Bokova, I. D. Romanov, and N. I. Shavlovsky. "Efficacy of undenatured and hydrolyzed type II collagen in the treatment of pain syndrome." Russian Medical Inquiry 6, no. 10 (2022): 571–75. http://dx.doi.org/10.32364/2587-6821-2022-6-10-571-575.

Full text

Abstract:

Collagens play an important structural role and contribute to the mechanical properties, organization and shape of tissues. In musculoskeletal system diseases (MSD), the amount of type II collagen in the cartilage extracellular matrix significantly decreases. Degradation and reduction of type II collagen are associated with osteoarthritis (OA). At present, SYSADOA (Symptomatic Slow Acting Drugs for Osteoarthritis) are widely used in the treatment of OA for oral and parenteral use. Besides, increased attention has been paid to the new treatment methods for OA based on a new promising type II collagen molecule: undenatured (UC-II) and hydrolyzed (HC-II) collagen. UC-II is a native collagen (fibrillar protein with a molecular weight of 300 kDa), whereas HC-II is a polypeptide (molecular weight of 2–9 kDa). The article describes the molecular mechanisms of action of UC-II and HC-II, and identifies the main differences between them. The diverse mechanism of action of the described collagen types determines their clinical use: UC-II is prescribed mainly in MSD, in particular OA, and HC-II is mainly used in cosmetology, as well as in MSD. The article also presents the study results demonstrating the safety and efficacy of drugs and dietary supplements containing UC-II and HC-II in relieving pain syndrome during OA. KEYWORDS: undenatured type II collagen native collagen, hydrolyzed collagen, collagen peptides, SYSADOA, pain syndrome, osteoarthritis. FOR CITATION: Shavlovskaya O.A., Bokova I.A., Romanov I.D., Shavlovsky N.I. Efficacy of undenatured and hydrolyzed type II collagen in the treatment of pain syndrome. Russian Medical Inquiry. 2022;6(10):571–575 (in Russ.). DOI: 10.32364/2587-6821-2022-6-10-571-575.

APA, Harvard, Vancouver, ISO, and other styles

14

Xue, I. B., P. G. Davey, and G. Phillips. "Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis." Antimicrobial Agents and Chemotherapy 40, no. 6 (June 1996): 1403–7. http://dx.doi.org/10.1128/aac.40.6.1403.

Full text

Abstract:

Initial measurements of postantibiotic effect (PAE) were made by a standard laboratory method (exposure to 1 mg of clindamycin per liter for 1 h). The range of PAE for 21 strains of Staphylococcus aureus isolated from osteomyelitis patients was 0.4 to 3.9 h, which markedly exceeded the coefficient of variation for the method (6 to 19%). Exposure of S. aureus to three doses of clindamycin at 8-h intervals had no consistent effect on either PAE or MIC. The PAE was dependent on both concentration and duration of exposure to clindamycin: for example, the PAEs for one strain were 1.7 h after exposure to 1 mg/liter for 1 h, 2.4 h after exposure to 4 mg/liter for 1 h, and 5.9 h after exposure to 4 mg/liter for 3 h. Pharmacokinetic simulations showed that the dose required to maintain free serum clindamycin concentrations above the MIC was 300 mg 6 hourly after oral administration (95% confidence interval, 243 to 301 mg) and 1.2 g 6 hourly (95% confidence interval, 305 to 1,145 mg) after intravenous (i.v.) administration. The duration of PAE would have to be at least 2.4 h to allow an increase in the oral dose interval to 8 h or to allow i.v. administration of 300 mg 6 hourly. Additional PAE experiments were performed with the three strains for which PAEs are the shortest after exposure to 1 mg/liter for 1 h (0.4 to 1.2 h). The PAE for these three strains increased markedly to 4.4 to 6.7 h following exposure to 2 mg/liter for 6 h (to mimic the area under the concentration-time curve from 0 to 6 h after a 300-mg dose). These data suggest that oral clindamycin could be administered at 300 mg 8 hourly in the treatment of S. aureus infection, whereas the i.v. dose interval should be 6 h. These suggestions should be confirmed by performing clinical trials.

APA, Harvard, Vancouver, ISO, and other styles

15

Prueksaritanond, Suartcha, Aram Barbaryan, Aibek E. Mirrakhimov, Palacci Liana, Alaa M. Ali, and Alan D. Gilman. "A Puzzle of Hemolytic Anemia, Iron and Vitamin B12 Deficiencies in a 52-Year-Old Male." Case Reports in Hematology 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/708489.

Full text

Abstract:

A 52-year-old male with no significant past medical history reports increasing generalized fatigue and weakness for the past 2 weeks. Physical examination reveals jaundice and pallor without organomegaly or lymphadenopathy. His hemoglobin was 5.9 g/dL with a mean corpuscular volume of 87.1 fL and elevated red blood cell distribution width of 30.7%. His liver function test was normal except for elevated total bilirubin of 3.7 mg/dL. Serum LDH was 701 IU/L, and serum haptoglobin was undetectable. Further investigation revealed serum vitamin B12 of <30 pg/mL with elevated methylmalonic acid and homocysteine level. In addition, serum ferritin and transferrin saturation were low. The patient was diagnosed with hemolytic anemia secondary to vitamin B12 deficiency with concomitant iron deficiency anemia.

APA, Harvard, Vancouver, ISO, and other styles

16

Christopherson, Kent W., Laura A. Paganessi, Darilyn R. Rhoades, Hortense M. Dillon, Sefer Gezer, Melissa L. Larson, Henry C. Fung, and Stephanie A. Gregory. "Abnormally High Levels of Circulating CD34+CD38−, CD34+CD38+, and CD10+ Hematopoietic Stem and Progenitor Cells in the Peripheral Blood of B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Suggest the Presence of Additional Therapeutic Target Cells." Blood 110, no. 11 (November 16, 2007): 4711. http://dx.doi.org/10.1182/blood.v110.11.4711.4711.

Full text

Abstract:

Abstract Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder manifested by a clonal expansion of mature long-lived functionally defective lymphocytes that are predominantly of B-cell origin (>95% of cases). CLL cells typically express the pan-B-cell antigens CD19 and CD20 as wells as CD5, an antigen of mature T-cells, which is present in 95% of B-CLL patients and is helpful for diagnosis. The disease has a median survival of 8–10 years. Asymptomatic patients (RAI stages 0–2) are often not treated. RAI stages 3 & 4 are generally treated. Current therapies for CLL included a combination of monoclonal antibodies (anti-CD20 monoclonal antibody, rituximab) with purine analogs (fludarabine or pentostatin) and alkylating agents (cyclophosphamide). Current therapies to manage B-cell CLL are not curative and therefore suggest that the current strategy of targeting therapy against B-cells may leave behind residual disease that contributes to progression or relapse. The importance of more primitive Hematopoietic Stem and Progenitor cell populations in B-CLL patients has not been considered. We hypothesized that circulating cells may be spontaneously mobilized into the periphery of CLL patients and would therefore contribute to the peripheral blood microenvironment. To test this hypothesis we examined existing CLL cell populations from un-treated “watch-and-wait” B-CLL patients as compared to normal volunteer donor peripheral blood cell populations utilizing multivariate flow cytometric analysis. We determined CD34+CD38−, CD34+CD38+, and CD10 levels in normal peripheral blood to be 81.0±14.5, 497.3±78.33, and 83.6±17.5 cells/ml respectively. We report here the presence of abnormally high levels of these stem and progenitor cell populations in B-CLL patients (see table). Although the mechanism behind the release of these cells into the periphery in B-CLL patients is unknown, it is reasonable to propose that they may be contributing to the manifestation of the disease and are therefore potential novel target cell populations for future therapies. B-CLL Patients WBC β2m CD34+CD38− CD34+CD38+ CD10+ White Blood Cell (WBC) counts are expressed as 1x106 cells/ml. All other counts are expressed as cells/ml 7.93 2.4 2,526 14.6 23,119 11.86 U 3,145 58.2 1,449 12.5 U 307 11.72 1,773 16.9 3.7 6,450 251 3,771 17.24 3.0 28 5.79 8,024 19.37 1.8 4,086 180 8,247 19.9 U 1,790 18.6 3,099 19.92 U 529 34.1 16,039 25.81 1.8 2,937 194 4,617 31.21 2.9 20,753 304 24,340 43.13 1.5 1,577 260.49 281,976 73.98 3.2 1,099 1,767 77,525 105.53 2.2 3,266 220 24,070

APA, Harvard, Vancouver, ISO, and other styles

17

Hambley, Trevor W., Keith G. Lewis, David J. Tucker, and Peter Turner. "Stereochemical Study of a 13β,28-Epoxyoleanane." Australian Journal of Chemistry 51, no. 4 (1998): 343. http://dx.doi.org/10.1071/c97109.

Full text

Abstract:

The stereochemistry of 3β-acetoxy-12α-bromo-13β,28-epoxyoleanan-16α-ol (2b) has been examined by n.m.r. methods and established by an X-ray crystallographic examination. Steric hindrance of the 16α-hydroxy group is shown not to be as great as previously reported. The bromo epoxide (2b), C32H51BrO4, M 579·66, crystallized in the orthorhombic space group P 212121 with a 16·118(2), b 16·615(3), c 11·024(7) Å, V 2952(1) Å3 , Dc(Z = 4) 1·304 g cm-3 , N = N(unique) = 1954, No 1731 [I > 2·5σ(I)], Nvar = 335, conventional R 0· 039, Rw 0·038.

APA, Harvard, Vancouver, ISO, and other styles

18

Ozdanova, Jitka, Helena Ticha, and Ladislav Tichy. "Some Physical Properties of Li₂O-TiO₂-TeO₂ and BaO-TiO₂-TeO₂ Glasses." Advanced Materials Research 39-40 (April 2008): 185–88. http://dx.doi.org/10.4028/www.scientific.net/amr.39-40.185.

Full text

Abstract:

Homogeneous yellowish and well transparent glasses (Li2O)x(TiO2)x(TeO2)1-2x and (BaO)x(TiO2)x(TeO2)1-2x , (x = 0.075, 0.1, 0.125) were prepared from corresponding oxides (purity 99+%). For prepared glasses the optical gap values were found in the region 3.2 eV – 3.4 eV and the temperature (T) coefficient of the optical gap (γ) varies in the narrow region 5.3×10-4 eV/K to 5.9×10-4 eV/K for 300 K < T < 580 K. Estimated values of non-linear refractive index (n2) were found in the region n2 [m2W-1] = 2.7×10-18 – 3.5×10-18 close to n2 values for similar glasses. Raman spectra measured indicate that connectivity of (BaO)x(TiO2)x(TeO2)1-2x network is more evolved than that one for (Li2O)x(TiO2)x(TeO2)1-2x glasses. TiO2 most probably assists to continuous network formation due to appearance of Te-O-Ti bridges.

APA, Harvard, Vancouver, ISO, and other styles

19

Di Veroli, Ambra, Marianna De Muro, Alessandro Andriani, Malgorzata Trawinska, Elena Rossi, Cristina Santoro, Sabrina Crescenzi Leonetti, et al. "Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN." Blood 128, no. 22 (December 2, 2016): 1951. http://dx.doi.org/10.1182/blood.v128.22.1951.1951.

Full text

Abstract:

Abstract Background Thrombotic episodes are the major complication in the follow-up of Philadelphia negative Myeloproliferative Neoplasms (MPN), with high morbidity and mortality, as reported in several retrospective studies. At present, however, few prospective data are available on the early incidence of these complications. Methods To address this issue, we report on 1087 patients [M/F 508/579, median age 67.6 years, interquartile range (IQR) 55.2 - 75.9] with newly diagnosed MPN enrolled in the prospective database of our regional cooperative group since January 2011. Of them, 571 (52.5%) had Essential Thrombocythemia (ET), 303 (27.9%) Polycythemia Vera (PV) and 213 (19.6%) Primary Myelofibrosis (PMF). The main clinical features at diagnosis of the whole cohort and according to the different MPNs are reported in the Table 1. Results On the whole, 22 episodes of thrombotic complications were reported in 1087 patients (2.0%) at a median interval from diagnosis of 18.2 months (IQR 7.4 - 29.7): in particular, 15 (68.1%) were arterial (8 cerebral, 2 coronaric, 4 in the lower limbs, 1 splancnic) and 7 (31.9%) venous (5 in the lower limbs and 2 in the upper limbs). As to the incidence of early thrombosis in the different MPNs, they were 13/571 (2.2%) in ET patients, 5/303 (1.6%) in PV patients and 4/213 (1.8%) in PMF patients (p=0.810): median time from diagnosis to thrombotic event was also similar in the 3 MPNs (p=0.311). The 4-year cumulative Thrombosis-Free Survival (TFS) of the whole cohort was 97.3% (95%CI 96.0 - 98.6): there was no difference among the 3 MPNs as to 4-year TFS [96.7% (95%CI 94.8 - 98.6) in ET, 97.8% (95%CI 95.9 - 99.7) in PV and 98.7% (95%CI 96.9 - 100) in PMF, respectively, p=0.668). Several clinical features at diagnosis (age, gender, Hb levels, WBC and PLT counts, spleen enlargement, JAK-2 V617F mutation and previous thrombotic events) were evaluated for a role in predicting thrombotic events: only age (p=0.009) and previous thrombotic events (p=0.009) were significant. Conclusions The incidence of early thrombosis seems low in the first 4 years after diagnosis of MPN based on our prospective database, without any difference among ET, PV and PMF: it is worth of note that only age and previous thrombotic events had a predictive role, thus confirming many retrospective reported data and reinforcing the prognostic value of old scoring system for thrombotic risk in MPN. Table 1 Table 1. Disclosures Breccia: Ariad: Honoraria; Pfizer: Honoraria; Novartis: Consultancy, Honoraria; Bristol Myers Squibb: Honoraria; Celgene: Honoraria. Latagliata:Novartis: Consultancy, Honoraria; Bristol Myers Squibb: Honoraria; Celgene: Honoraria; Janssen: Consultancy, Honoraria; Shire: Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

20

Ghosh, D., S. Hussain, B. Ghosh, R. Bhar, and A. K. Pal. "Stress and Grain Boundary Properties of GaN Films Prepared by Pulsed Laser Deposition Technique." ISRN Materials Science 2014 (March 17, 2014): 1–10. http://dx.doi.org/10.1155/2014/521701.

Full text

Abstract:

Polycrystalline gallium nitride films were successfully deposited on fused silica substrates by ablating a GaN target using pulsed Nd-YAG laser. Microstructural studies indicated an increase in the average crystallite size from ~8 nm to ~70 nm with the increase in substrate temperature from 300 K to 873 K during deposition. The films deposited here were nearly stoichiometric. XPS studies indicated two strong peaks located at ~1116.6 eV and ~395 eV for Ga2p3/2 and a N1s core-level peak, respectively. The films deposited at substrate temperature above 573 K are predominantly zinc blende in nature. PL spectra of the films deposited at higher temperatures were dominated by a strong peak at ~3.2 eV. FTIR spectra indicated a strong and broad absorption peak centered ~520 cm−1 with two shoulders at ~570 cm−1 and 584 cm−1. Characteristic Raman peak at ~531 cm−1 for the A1(TO) mode is observed for all the films. Grain boundary trap states varied between 3.1×1015 and 7×1015 m−2, while barrier height at the grain boundaries varied between 12.4 meV and 37.14 meV. Stress in the films decreased with the increase in substrate temperature.

APA, Harvard, Vancouver, ISO, and other styles

21

Singh, Khushwant, Matthew Huff, Jianyang Liu, Jong-Won Park, Tara Rickman, Manjunath Keremane, Robert R. Krueger, et al. "Chromosome-Scale, De Novo, Phased Genome Assemblies of Three Australian Limes: Citrus australasica, C. inodora, and C. glauca." Plants 13, no. 11 (May 24, 2024): 1460. http://dx.doi.org/10.3390/plants13111460.

Full text

Abstract:

Huanglongbing (HLB) is a severe citrus disease worldwide. Wild Australian limes like Citrus australasica, C. inodora, and C. glauca possess beneficial HLB resistance traits. Individual trees of the three taxa were extensively used in a breeding program for over a decade to introgress resistance traits into commercial-quality citrus germplasm. We generated high-quality, phased, de novo genome assemblies of the three Australian limes using PacBio long-read sequencing. The genome assembly sizes of the primary and alternate haplotypes were determined for C. australasica (337 Mb/335 Mb), C. inodora (304 Mb/299 Mb), and C. glauca (376 Mb/379 Mb). The nine chromosome-scale scaffolds included 86–91% of the genome sequences generated. The integrity and completeness of the assembled genomes were estimated to be at 97.2–98.8%. Gene annotation studies identified 25,461 genes in C. australasica, 27,665 in C. inodora, and 30,067 in C. glauca. Genes belonging to 118 orthogroups were specific to Australian lime genomes compared to other citrus genomes analyzed. Significantly fewer canonical resistance (R) genes were found in C. inodora and C. glauca (319 and 449, respectively) compared to C. australasica (576), C. clementina (579), and C. sinensis (651). Similar patterns were observed for other gene families associated with potential HLB resistance, including Phloem protein 2 (PP2) and Callose synthase (CalS) genes predicted in the Australian lime genomes. The genomic information on Australian limes developed in the present study will help understand the genetic basis of HLB resistance.

APA, Harvard, Vancouver, ISO, and other styles

22

Röhling, Martin, Kerstin Kempf, Winfried Banzer, Klaus Michael Braumann, Dagmar Führer-Sakel, Martin Halle, David McCarthy, et al. "A High-Protein and Low-Glycemic Formula Diet Improves Blood Pressure and Other Hemodynamic Parameters in High-Risk Individuals." Nutrients 14, no. 7 (March 30, 2022): 1443. http://dx.doi.org/10.3390/nu14071443.

Full text

Abstract:

Low-caloric formula diets can improve hemodynamic parameters of patients with type 2 diabetes. We, therefore, hypothesized that persons with overweight or obesity can benefit from a high-protein, low-glycemic but moderate-caloric formula diet. This post-hoc analysis of the Almased Concept against Overweight and Obesity and Related Health Risk- (ACOORH) trial investigated the impact of a lifestyle intervention combined with a formula diet (INT, n = 308) compared to a control group with lifestyle intervention alone (CON, n = 155) on hemodynamic parameters (systolic and diastolic blood pressure (SBP, DBP), resting heart rate (HR), and pulse wave velocity (PWV)) in high-risk individuals with prehypertension or hypertension. INT replaced meals during the first 6 months (1 week: 3 meals/day; 2–4 weeks: 2 meals/day; 5–26 weeks: 1 meal/day). Study duration was 12 months. From the starting cohort, 304 (68.3%, INT: n = 216; CON: n = 101) participants had a complete dataset. Compared to CON, INT significantly reduced more SBP (−7.3 mmHg 95% CI [−9.2; −5.3] vs. −3.3 mmHg [−5.9; −0.8], p < 0.049) and DBP (−3.7 mmHg [−4.9; −2.5] vs. −1.4 mmHg [−3.1; 0.2], p < 0.028) after 12 months. Compared to CON, INT showed a pronounced reduction in resting HR and PWV after 6 months but both lost significance after 12 months. Changes in SBP, DBP, and PWV were significantly associated positively with changes in body weight and fat mass (all p < 0.05) and resting HR correlated positively with fasting insulin (p < 0.001) after 12 months. Combining a lifestyle intervention with a high-protein and low-glycemic formula diet improves hemodynamic parameters to a greater extent than lifestyle intervention alone in high-risk individuals with overweight and obesity.

APA, Harvard, Vancouver, ISO, and other styles

23

Hagiwara, Yoshiaki, Christian Henkel, and William A. Sherwood. "Monitoring of extragalactic water masers with the MPIfR 100-m telescope." Symposium - International Astronomical Union 206 (2002): 392–95. http://dx.doi.org/10.1017/s0074180900222766.

Full text

Abstract:

We present single-dish monitoring of the 22 GHz water maser lines from the Seyfert 2 galaxies NGC 3079, M51(NGC 5194), NGC 5793, and the radio galaxy NGC 315 with the Effelsberg 100-m radio telescope. During the monitoring period of 1995 − 2001, the H2O masers flared in M51 and NGC 5793, while maser emission from NGC 315 was not detected in 1996 and 2000. During 2000, we discovered new red-shifted velocity features in NGC 3079 and blue-shifted features in M51. These velocity components are crucial to model the distribution of maser emission in each galaxy.

APA, Harvard, Vancouver, ISO, and other styles

24

Silverberg, Nanette, Harry M. Meister, and Mark Lebwohl. "571 - Case series of topical 1.5% ruxolitinib cream for pediatric vitiligo." British Journal of Dermatology 190, Supplement_2 (February 2024): ii71—ii72. http://dx.doi.org/10.1093/bjd/ljad498.073.

Full text

Abstract:

Abstract Introduction/Background Pediatric Vitiligo affects 1.52% of 4-11-year-olds within the United States and 2.16% of 12-17-year-olds with non-segmental disease affecting 65% and 69% respectively (1). The FDA has not approved any medications for vitiligo for children younger than 12 years of age. Additionally, about one-third of pediatric vitiligo is segmental (1), and there is no FDA-approved topical agent for segmental vitiligo in any pediatric age group (2). Objectives To identify the efficacy of 1.5% ruxolitinib cream for pediatric vitiligo in clinical practice. Methods An IRB-exempted pediatric chart review was conducted addressing the usage of 1.5% ruxolitinib cream, currently FDA-approved for non-segmental vitiligo affecting 10% of body surface area or less for 12 years of age or older. All children and adolescents using topical 1.5% ruxolitinib cream including segmental, non-segmental, and mixed vitiligo including individuals up to age 17 years. Results Twelve children were identified with topical usage of 1.5% ruxolitinib cream for vitiligo ages 3-16 years (average age: 10.75 years). Demographics included 9 males, 3 females and race/ ethnicity included Black (n=1), Hispanic/ Latin X (n=4), Indian (n=1), and White (n=6). Vitiligo subtype included: Non-segmental vitiligo (n=7), Mixed type vitiligo (n=1), and segmental vitiligo (n=4). Regarding treatment subgroup of Non-segmental vitiligo and the non-segmental component of the Mixed type included 8 children, average age of 10.4 years (range 3-15 years), including 5 children under the age of 12 years (one 3-year-old, two 9 year-olds, and two 10 year-olds). Treatment was once daily in 1 child and twice daily in 7 children. One was lost to follow-up. Of the 6 children with documented response, average maximum repigmentation occurred at 6.14 months (range 3-12 months), with five achieving complete repigmentation, one partial repigmentation with only a three-month trial. The average length of disease before treatment began was 1.25 years (1 month to 6 years). The onset of response was 1.57 months on average (range 1-3 months). The initial location of response was the face (n=3), arms (n=2), and abdomen (n=1). No adverse events were reported. Four children had a complete blood count while on medication, with no laboratory abnormalities, including the 3-year-old. Two had a parent with vitiligo. Four patients previously failed tacrolimus topically, two patients failed topical class 2 corticosteroids, and one previously failed narrowband UVB, with no notable difference in response in these patients. Regarding treatment subgroup of Segmental vitiligo including five SV patients average age 11.2 years (range 5-16 years). One had facial segmental, one face and neck lesion (solitary stripe), one chest/back, and one on the lower abdomen. The five year-old did not repigment after 6 months of neck application, but never developed poliosis. The ten-year-old with segmental disease for 6 years had no response. The eleven-year-old SV of the chest/ back failed topical tacrolimus and responded with 40% repigmentation over 3 months, increasing to 90% after 5 months and 12 concurrent sessions of 308-nm laser. The 14-year-old developed slight poliosis, but started repigmenting within 3 weeks, with continuous usage and subtotal repigmentation at 14 months. The 16-year-old began to repigment after 1 month, with a concurrent weekly 308-nm laser, and subtotal repigmentation after 5 months. Repigmentation was One facial SV (12 treatments), one chest/back SV (12 treatments), and one NSV had concurrent 308-nm laser (24 treatments) with pulsed dexamethasone, without any notable adverse events. Two teenage males (ages 15 and 16 years) developed acne on sites of application on the face. Laboratory screening including complete blood count was normal during treatment for 2 patients evaluated. Conclusions NSV responds to 1.5% topical ruxolitinib consistently, with a solitary patient responding to once daily, and efficacy in children as young as three years of age with no notable lab abnormalities in screened patients. Topical 1.5% ruxolitinib cream appears very effective in repigmenting SV in children if used twice-daily and in combination with 308-nm laser sessions in the first 6 months. Topical ruxolitinib can cause acne in teenagers with facial segmental vitiligo. Early institution of topical 1.5% ruxolitinib cream appears to have a rapid onset of repigmentation (average 1.57 months) and rapid complete response (6.14 months). Clinical trials of 1.5% topical ruxolitinib in children are needed to identify outliers and long term outcomes. Early institution of therapy appears to speed up the response. Adjunctive 308-nm laser is promising but requires placebo-controlled trials.

APA, Harvard, Vancouver, ISO, and other styles

25

Shi, Feng, Yu Fen Gu, and Cui Xia Li. "Growth of β-Ga₂O₃ Nanoparticles Doped with Tin by Ni²⁺ Catalyzed Chemical Vapor Deposition." Advanced Materials Research 873 (December 2013): 200–205. http://dx.doi.org/10.4028/www.scientific.net/amr.873.200.

Full text

Abstract:

Sn-doped monoclinic β-Ga2O3 nanoparticles were successfully fabricated on Si (111) substrates with NiCl2 as a catalyst by chemical vapor deposition using metallic gallium and oxygen as sources. The composition, crystal structure, morphology, and optical properties were characterized by X-ray diffraction, scanning electron microscopy, Fourier-transform infrared spectrophotometry (FTIR), and photoluminescence, respectively. The results demonstrate that the sample was monoclinic β-Ga2O3 nanoparticles with diameters approximately ranging from 200~300 nm. Well-defined prominent absorption bands located at 458 and 671 cm-1 in the FTIR spectra corresponded to Ga-O vibrations. The photoluminescence spectrum shows that the Ga2O3 nanoparticles have a broad and strong emission band ranging from 300 nm to 650 nm with four Gaussian bands centered at approximately 346 (UV), 416 (blue), 473 (dark blue), and 529 nm (green), which may be attributed to defects such as oxygen vacancies and galliumoxygen vacancy pairs. The growth mechanism of β-Ga2O3 nanoparticles is discussed in brief.

APA, Harvard, Vancouver, ISO, and other styles

26

Depauw, R. M., R. E. Knox, A. K. Singh, T. N. Mccaig, J. M. Clarke, and R. D. Cuthbert. "NRG010 General Purpose spring wheat." Canadian Journal of Plant Science 93, no. 3 (May 2013): 549–55. http://dx.doi.org/10.4141/cjps2012-309.

Full text

Abstract:

DePauw, R. M., Knox, R. E., Singh, A. K., McCaig, T. N., Clarke, J. M. and Cuthbert, R. D. 2013. NRG010 General Purpose spring wheat. Can. J. Plant Sci. 93: 549–555. Based on 26 trials over 2 yr, the cultivar NRG010 yielded similar to the General Purpose checks Hoffman and AC Andrew. NRG010 had significantly shorter stature than Hoffman. NRG010 had a large white kernel intermediate in size to AC Andrew and Hoffman. NRG010 expressed resistance to prevalent races of leaf rust, stem rust and common bunt, and moderate susceptibility to prevalent races of loose smut and fusarium head blight. NRG010 is eligible for the Canada General Purpose wheat class.

APA, Harvard, Vancouver, ISO, and other styles

27

Bunak, M. S., M. V. Vishnyakova, G. A. Stashuk, and R. G. Biktimirov. "Using the arterial spins labeling method (ASL-perfusion) for evaluation of glioblastoma residual tissue." Journal of radiology and nuclear medicine 99, no. 6 (January 2, 2019): 305–9. http://dx.doi.org/10.20862/0042-4676-2018-99-6-305-309.

Full text

Abstract:

Objective. To evaluate the efficiency of ASL-perfusion as a method of estimating of hemodynamics and detection of residual tumor tissue after surgical treatment of glioblastoma.Material and methods. 56 patients after brain tumor’s surgical resection of glioblastoma (GRADE IV). CBF values were determined in 3 different areas - in the presumed tumor tissue with maximum perfusion, in the postoperative scar tissue and in the deep white matter of the opposite hemisphere. All patients were divided into 2 groups according to CBF value.Results. 1st group: 38 (67.9%) patients - the average CBF in suspected tumor was 137.6±35.2 (79.6-227.6) ml/100 g/min. It was 6-8 times higher than CBF in the deep white matter of the opposite hemisphere, and 5-6 times higher than in the postoperative scars.2nd group: 18 (32.1%) patients with no pathological elevation of CBF in postoperative scar tissue. CBF there was 22.3±5.9 (13.9-37.1) ml/100 g/min. CBF in white matter in the contralateral hemisphere was similar.There was no significant differences in CBF of scar tissue (p=0,52) and in white matter of contralateral hemisphere (p=0,96) in both groups.Conclusion. The possibilities of ASL-perfusion are enough to estimating of hemodynamics and detection of residual tumor tissue after surgical removed glioblastoma.

APA, Harvard, Vancouver, ISO, and other styles

28

Nguyen Van, Long, and Hoang Son Tong Phuoc. "Temporal changes of key marine habitats in the World Biosphere Reserve of Cu Lao Cham - Hoi An, Quang Nam province." Tạp chí Khoa học và Công nghệ Biển 21, no. 2 (June 30, 2021): 191–200. http://dx.doi.org/10.15625/1859-3097/15063.

Full text

Abstract:

Assessments of marine habitats have played an essential role in the management and sustainable uses of marine biodiversity resources. Spatial and temporal changes in distribution and area of crucial marine habitats in the World Biosphere Reserve of Cu Lao Cham - Hoi An were assessed using remote sensing technology (Landsat 5-TM, SPOT4, and AVNIR2 Sentinel 2-MS) and aerial images in combination with ground-truthing at 60 key sites in the year of 2016 and back-interpretation for the years of 2004 and 2008. This study shows some 579 ha of coral reefs, 117 ha of mangrove forest (mainly by Nypa palm), and 43 ha of seagrass beds recorded in 2016. There was some 112.5 ha, including 77.1 ha of the Nypa palm in the Thu Bon estuaries, 34.6 ha of seagrass beds (Bai Ong and Bai Huong in Cu Lao Cham islands), and 0.8 ha of coral reefs lost between 2004 and 2016 due to development of infrastructure and marine culture. The declines of the Nypa palm and the seagrass beds in the Thu Bon estuaries have been threatening to the maintenance of essential nursery grounds of target species, especially in the area surrounding the Nypa palm forest “rung dua bay mau” at Cam Thanh commune.

APA, Harvard, Vancouver, ISO, and other styles

29

Ahn, Hee Kyung, Jee Hung Kim, Mirae Kim, Seri Park, Su-Jin Koh, Joo Hyuk Sohn, Myoung Joo Kang, et al. "Abstract P5-03-14: Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study." Cancer Research 83, no. 5_Supplement (March 1, 2023): P5–03–14—P5–03–14. http://dx.doi.org/10.1158/1538-7445.sabcs22-p5-03-14.

Full text

Abstract:

Abstract Backgrounds Since OlympiAD study, National Comprehensive Cancer Network guideline recommends assessment of germline BRCA1/2 mutation in all patients with recurrent or metastatic breast cancer to identify candidates for PARP inhibitor therapy, which is not always possible in clinical practice due to limited resources for testing. Data on the prevalence of gBRCA mutation is still lacking, especially in patients with non-high risk for hereditary breast and ovarian cancer syndrome. In this study, we investigated prevalence of gBRCA mutation in unselected Korean patients with HER2-negative advanced BC in a prospective cohort and analyzed oncologic outcome. Methods Eligible patients were diagnosed with HER2-negative advanced BC and had initiated palliative systemic treatment. Peripheral blood was prospectively drawn from each patient and gBRCA mutation status was assessed by next generation sequencing using NGeneBio BRCAaccuTest®. In 100 patients, somatic mutations including BRCA1/2 from tumor tissue were investigated using targeted panel sequencing. To estimate the prevalence of gBRCA mutation with margin of error to be no more than ±4% at the 95% confidence interval in a population size of 20,000, 583 patients were to be enrolled. Results A total of 583 patients were enrolled between Oct 2019 and Mar 2022, and the prevalence of gBRCA mutation was analyzed in 570 patients, excluding ineligible patients. Median age was 54 years old (range 26-87) and 567 patients were female. 475 patients had HR+/HER2- BC and 94 patients had triple negative breast cancer (TNBC). The overall prevalence of gBRCA1/2 pathogenic mutation was 7.3% (42/570) in unselected patients. The prevalence of gBRCA1 mutation was 1.6%(9/570) overall, 0.8%(4/475) in HR+/HER2- BC, and 5.3%(5/94) in TNBC. The prevalence of gBRCA2 mutation was 5.8%(33/570) overall, 6.3%(30/475) in HR+/HER2- BC, 3.2%(3/94) in TNBC. Prevalence in low risk TNBC (>60 years at first BC diagnosis, no known family history of relevant cancer and unilateral breast cancer) was 10.5% (2/19, all 2 patients had gBRCA2 mutation). Prevalence in low risk HR+/HER2- (>40 years at first BC diagnosis, no known family history of relevant cancer and unilateral breast cancer) was 5.9% (18/307, 17 patients had gBRCA2 mutation). The overall prevalence of gBRCA1/2 pathogenic mutation in Korean patients with low risk HER2-negative advanced BC was 6.1%. The result of somatic mutation, treatment patterns and clinical outcome according to gBRCA1/2 mutation will be further analyzed. Conclusions The prevalence of gBRCA mutation among Korean patients with HER2-negative advanced BC classified as low risk (6.1%) in this study supports routine testing of gBRCA mutation in this population. Citation Format: Hee Kyung Ahn, Jee Hung Kim, Mirae Kim, Seri Park, Su-Jin Koh, Joo Hyuk Sohn, Myoung Joo Kang, Kyung Hae Jung, Kyoung Eun Lee, Jieun Lee, Sung Ae Koh, Yee Soo Chae, Jae Ho Byun, In Hae Park, Hee-Jun Kim, Jee Hyun Kim, Han Jo Kim, Joo Young Jung, Jung Lim Lee, Yoon Young Cho, Kyong Hwa Park, Ji-Yeon Kim, Seock-Ah Im, Yeon Hee Park. Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-03-14.

APA, Harvard, Vancouver, ISO, and other styles

30

Zsolt, Szentkereszty, Trungel Enikő, Pósán János, Sápy Péter, Szerafin Tamás, and Sz Kiss Sándor. "Áthatoló mellkassérülések diagnózisának és kezelésének időszerű kérdéseir." Magyar Sebészet 60, no. 4 (August 1, 2007): 199–204. http://dx.doi.org/10.1556/maseb.60.2007.4.1.

Full text

Abstract:

Absztrakt Bevezetés: Az áthatoló mellkasi sérülések sikeres kezelése a korrekt, gyors diagnózisban és az adekvát sebészi kezelésben rejlik. A szerzők 109 mellkassérült beteg kapcsán értékelik a diagnózis és a kezelés aktuális kérdéseit a szövődmények és az eredmények tükrében. Betegek és módszerek: A 82 férfi és 27 nő sérült átlagos életkora 37,8 év volt. A sérülést 104 (95,4%) esetben szúrás, 4 (3,7%) esetben lövés és 1 (0,9%) esetben robbanás okozta. A 41 szív- és szívburoksérültnél 19 (46,3%) mellkas-rtg, 9 (22%) echocardiographia és 2-2 CT-vizsgálat, illetve diagnosztikus VATS történt. A 41 beteg közül 40-et megoperáltunk. A 68 nem szívtáji sérültnél minden esetben készült mellkas-rtg. 6 (8,8%) betegnél echokardiographia, 4-nél (5,9%) diagnosztikus VATS és 3-nál (4,4%) hasi UH készült. A betegek közül 13 (19,1%) esetben mellkas-drainage, 51 betegnél nyitott műtét és 4 betegnél VATS történt. Eredmények: A szív- és szívburoksérülteknél a mellkas-rtg, az echocardiographia és a VATS szenzitivitása 57,9%, 88,9%, illetve 100%, specificitása 26,3%, 88,9%, illetve 100% volt. A nem szívtáji sérülteknél a mellkas-rtg szenzitivitása 100%, a VATS szenzitivitása és specificitása egyaránt 100% volt. A posztoperatív szövődmények aránya 12,6% volt, mely a szívsérülteknél 15%, a nem szívtáji sérülteknél 10,9% volt. Halálozás csak a szívsérülteknél (7,3%) volt. Az átlagos halálozás 2,8% volt. Következtetés: Az áthatoló mellkasi sérültek életesélyei a gyors és célzott diagnosztikus tevékenységet követő korrekt kezelésnek köszönhetően biztatóak.

APA, Harvard, Vancouver, ISO, and other styles

31

Family, Leila, Su-Jau Yang, Zandra Klippel, Yanli Li, John H. Page, Roberto Rodriguez, and Chun Chao. "Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens." Blood 126, no. 23 (December 3, 2015): 3257. http://dx.doi.org/10.1182/blood.v126.23.3257.3257.

Full text

Abstract:

Abstract Introduction Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy, which often results in hospitalization and chemotherapy dose modification. FN risk depends on patient characteristics and chemotherapy regimen risk. Understanding the FN risk associated with individual chemotherapy regimens can help guide the use of prophylactic granulocyte colony-stimulating factor (G-CSF) and patient monitoring. To this end, the NCCN has classified regimens into high (≥20%), intermediate (10%-20%), or low (<10%) FN risk based primarily on clinical trial data. However, even for the same regimen, the FN risk is often higher in clinical practice than in clinical trials. In this study, we assessed the FN risk associated with several regimens for which FN risk has not been determined or has shown substantial variability outside of a clinical trial setting, using data from Kaiser Permanente Southern California (KPSC), a large, community-based practice. Methods Included were patients diagnosed with incident non-Hodgkin's lymphoma (NHL), breast cancer (BC), or multiple myeloma (MM) between 2008 and 2013 at KPSC who initiated the following chemotherapy regimens: bendamustine ± rituximab for NHL; docetaxel, carboplatin, and trastuzumab (TCH) or docetaxel and cyclophosphamide (TC) for BC; or Q4W lenalidomide 25 mg/dexamethasone for MM. Bendamustine ± rituximab, TCH, and lenalidomide are not classified by NCCN; TC is classified as intermediate FN risk but has shown considerable variability of FN incidence when used in clinical practice. Data on cancer diagnosis, chemotherapy use, G-CSF use, neutrophil count, and infections were obtained from KPSC's electronic medical records to estimate the incidence proportions of FN and grade 3 and 4 neutropenia. FN was defined as (1) hospitalization with absolute neutrophil count (ANC) <1000/µL or (2) hospitalization with primary or secondary diagnosis codes of neutropenia (ICD-9 288.0x) and fever (ICD-9 780.6), diagnosis code for bacterial/fungal infection, or antibiotic use. Grade 3 neutropenia was defined as ANC ≥500/µL to <1000/µL; grade 4 neutropenia as ANC <500/µL. Patients who received prophylactic G-CSF within 5 days of chemotherapy initiation were excluded from analysis. Results Overall, 40 (12%) NHL patients; 149 (24%) and 340 (28%) BC patients who received TCH and TC, respectively; and 0 (0%) MM patients were excluded due to prophylactic G-CSF. Over the first 6 cycles of bendamustine (median 338.4 mg/m2) ± rituximab for NHL patients (n = 307), 7.2% experienced FN, 4.2% grade 3 neutropenia, and 17.6% grade 4 neutropenia. Over the first 6 cycles of TCH for BC patients (n = 462), 24.2% experienced FN, 10.6% grade 3 neutropenia, and 44.6% grade 4 neutropenia. Over the first 6 cycles of TC for BC patients (n = 859), 20.5% experienced FN, 9.5% grade 3 neutropenia, and 37.5% grade 4 neutropenia. Over the first 4 cycles of lenalidomide/dexamethasone for MM patients (n = 186), 3.8% experienced FN, 5.9% grade 3 neutropenia, and 18.3% grade 4 neutropenia (Table 1). Conclusions Using NCCN criteria, bendamustine ± rituximab for NHL and lenalidomide/dexamethasone for MM would be classified as low-FN-risk regimens (<10%). By contrast, BC regimens TCH and TC would be classified as high-FN-risk regimens (>20%) based on our data. These results could help inform prophylactic G-CSF use for the selected regimens in clinical practice. Table 1. Number and Incidence Proportion of Neutropenic Outcomes Overall and by Cycle Cancer: Regimen Cycle Patients n FN Events n (%) Grade 3 Neutropenia Events n (%) Grade 4 Neutropenia Events n (%) NHL: Bendamustine ± rituximab Overall 307 22 (7.2) 13 (4.2) 54 (17.6) 1 307 12 (3.9) 5 (1.6) 28 (9.1) 2 225 3 (1.3) 4 (1.8) 21 (9.3) 3 173 2 (1.2) 4 (2.3) 15 (8.7) 4 130 2 (1.5) 4 (3.1) 10 (7.7) 5 92 4 (4.4) 4 (4.4) 8 (8.7) 6 69 2 (2.9) 2 (2.9) 0 (0) BC: TCH Overall 462 112 (24.2) 49 (10.6) 206 (44.6) 1 462 70 (15.2) 39 (8.4) 138 (29.9) 2 326 13 (4.0) 15 (4.6) 42 (12.9) 3 282 17 (6.0) 9 (3.2) 39 (13.8) 4 247 6 (2.4) 8 (3.2) 31 (12.6) 5 199 4 (2.0) 6 (3.0) 25 (12.6) 6 169 8 (4.7) 3 (1.8) 12 (7.1) BC: TC Overall 859 176 (20.5) 82 (9.5) 322 (37.5) 1 859 126 (14.7) 51 (5.9) 266 (30.9) 2 649 21 (3.2) 42 (6.5) 82 (12.6) 3 571 19 (3.3) 23 (4.0) 62 (10.9) 4 511 14 (2.7) 22 (4.3) 45 (8.8) 5 94 1 (1.1) 3 (3.2) 9 (9.6) 6 84 2 (2.4) 1 (1.2) 2 (2.4) MM: Lenalidomide / dexamethasone Overall 186 7 (3.8) 11 (5.9) 34 (18.3) 1 186 2 (1.1) 8 (4.3) 17 (9.1) 2 101 3 (3.0) 5 (5.0) 14 (13.9) 3 63 2 (3.2) 2 (3.2) 8 (12.7) 4 37 0 (0) 0 (0) 4 (10.8) Disclosures Family: Amgen Inc.: Research Funding. Klippel:Amgen Inc.: Employment, Equity Ownership. Li:Amgen Inc.: Employment, Equity Ownership. Page:Amgen Inc.: Employment, Equity Ownership.

APA, Harvard, Vancouver, ISO, and other styles

32

Schmickler, Wolfgang. "Rundum nützlich: Elektrochemisches Praktikum. Von Rudolf Holze. B. G. Teubner, Stuttgart 2001. 302 Seiten, brosch. 32,72 Euro. ISBN 3-519-03614-2." Nachrichten aus der Chemie 50, no. 2 (February 2002): 192. http://dx.doi.org/10.1002/nadc.20020500226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Martín Riego, Manuel. "María Antonia Bel Bravo, La familia en la historia (Madrid, Encuentro, 2000) 302 pp. 230 X 150. ISBN 84-7490-570-2." Isidorianum 10, no. 19 (May 1, 2001): 271–72. http://dx.doi.org/10.46543/isid.0210.1014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Hafeez, Shaista, Karole Warren-Oseni, Helen McNair, Vibeke Hansen, Fiona McDonald, Susan Lalondrelle, Alan Thompson, et al. "Prospective phase 1 study assessing feasibility of IMRT and IGART to deliver simultaneous integrated high-dose tumor boost (up to 70 Gy) for the radical treatment of localized muscle-invasive bladder cancer." Journal of Clinical Oncology 33, no. 7_suppl (March 1, 2015): 307. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.307.

Full text

Abstract:

307 Background: Advances in IGART offer individualized solutions to improve target coverage and reduce normal tissue irradiation allowing opportunity to increase radiation tumour dose and spare normal bladder. Methods: A library of 3 IMRT plans were created (small, medium and large) from planning CT scans performed at 30 and 60 minutes; treating whole bladder to 52 Gy and tumour to 70 Gy in 32 fractions. Where normal tissue dose constraints were not met consideration was made to boosting tumour to lower dose (68 Gy-64 Gy). Cone beam CT (CBCT) imaging was performed prior to each fraction. Appropriate PTV was selected from the library for treatment delivery. Post treatment CBCT was acquired weekly in order to assess intra-fraction filling and coverage. Results: 22 patients have been planned using this technique. All have met tissue constraints for treatment to 70 Gy. 21 patients have completed radiotherapy, 18 completed treatment to 70 Gy; 1 patient was planned and treated to 68 Gy prior to dose escalation using this technique; 1 patient was treated to a total dose of 65.6 Gy because dose limiting toxicity occurred before dose escalation. 572 CBCTs have been evaluated. Treatment was delivered using small, medium, and large plans in 35%, 52%, and 13% cases respectively. Mean intra-fraction filling was 14 cm3 (SD 16.3, range 0.23-107.9). Mean time between pre- and post-CBCTs was 13 min (SD 2.1, range 9-18). Mean D 98% as assessed on post-radiotherapy CBCT was 98.7% (SD 1.78, range 89.9-100%). At median follow-up of 8 months (range 1-24 months), 18 patients remain alive and disease free. 2 superficial recurrences and 3 deaths from metastatic bladder cancer have occurred. No muscle invasive recurrences have occurred within this cohort. Using this technique one patient has experienced late toxicity (grade 3 cystitis) 5.3 months after radiotherapy (now resolved). Conclusions: IGART using IMRT to delivery a simultaneous integrated tumour boost is feasible with acceptable toxicity. Trial recruitment continues at 70 Gy and will be evaluated in a randomised trial (RAIDER). Clinical trial information: NCT01124682.

APA, Harvard, Vancouver, ISO, and other styles

35

Schlegelmilch, Michael, Salima Punja, Hsing Jou, Andrew S. Mackie, Jennifer Conway, Bev Wilson, Maria Spavor, Dawn Hartfield, and Sunita Vohra. "Observational Study of Pediatric Inpatient Pain, Nausea/Vomiting and Anxiety." Children 6, no. 5 (May 3, 2019): 65. http://dx.doi.org/10.3390/children6050065.

Full text

Abstract:

Background: The prevalence and severity of pain, nausea/vomiting, and anxiety (PNVA) among hospitalized children is not well established. We describe the prevalence and severity of PNVA among hospitalized patients from oncology, general pediatrics, and cardiology services in a tertiary care center. Methods: Patients were recruited on admission and enrolled if their caregiver consented, spoke English, and were anticipated to stay 2–30 days. Symptoms were measured weekdays using age-validated tools. PNVA symptoms were described and compared. Results: We enrolled 496 (49.4%) patients of 1005 admitted. Patients were predominantly Caucasian (57.9%) on their first admission (53.6%). The average (SD) age was 8.6 years (5.9) in oncology, 4.2 (5.3) in general pediatrics and 2.6 (4.0) in cardiology. 325 (65.6%) patients reported anxiety, 275 (55.4%) reported nausea and 256 (52.0%) reported pain. Mean (SD) severity out of 10 was 3.7 (2.5) for anxiety, 3.2 (2.1) for nausea and 3.0 (1.5) for pain. Prevalence of PNVA was no different between clinical programs, but pain (p = 0.008) and nausea (p = 0.006) severity were. PNVA symptom co-occurrence was positively correlated (p < 0.001). Conclusions: Anxiety was the most common and severe symptom for hospitalized children. Patients in oncology demonstrated the least severe pain and nausea with no difference in anxiety between services.

APA, Harvard, Vancouver, ISO, and other styles

36

Lambert-Falls, R., M. A. Deutsch, C. Desch, K. Zhou, and E. Perez. "Phase III adjuvant trial of concurrent epirubicin/taxane vs. sequential epirubicin/cyclophosphamide followed by taxane for node positive breast cancer." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 573. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.573.

Full text

Abstract:

573 Background: This study evaluates whether concurrent epirubicin/taxane (ET) improves disease-free survival (DFS) at 3 yrs compared to the sequential combination of epirubicin/cyclophosphamide followed by a taxane (EC>T) in pts with operable node (+) breast cancer. Methods: Eligible pts were randomized to receive either ET (E 75 mg/m 2) for 8 cycles q21 days or EC>T (E 90 mg/m 2, C 600 mg/m2) for 4 cycles, followed by 4 cycles of a taxane q21 days. Choice of T (paclitaxel 175 mg/m2 or docetaxel 75 mg/m 2) was at the physician’s discretion. The primary endpoint is DFS. A 0.10 increase in the probability of DFS at 3 yrs for the ET arm would be considered clinically relevant. To detect 82 events, 300 subjects per arm are required to provide 90% power at 5% significance level. Results: 617 pts were enrolled from Nov 2000 to June 2003; 308 pts received ET and 309 pts received EC>T. Both treatment arms were well balanced with respect to age, nodal+, ER status, Her-2+ and PS; median age 52.5 (42%<50 years old); 70% ER+; 61% LN (1–3); 16% Her-2+; 87% PS 0. Total of 2206 cycles of treatment were given to ET compared 2314 cycles of treatment to EC>T. At 30 months of median follow-up there were DFS 102 events occurred; 47 events in ET arm (16%) and 55 events in EC>T arm (18%); 63 total deaths; 29 deaths in ET arm and 34 deaths in EC>T arm. The most common toxicities include alopecia (50%), fatigue (31%), nausea and vomiting (30%), dyspepsia (27%), febrile neutropenia (15%), constipation (12%), diarrhea (10%), arthralgia (11%), stomatitis (10%). In cardiac safety f/u, only one pt in ET arm remained LVEF drop >15. Conclusions: Epirubicin can be combined with taxanes in both sequential and concurrent therapies and both regimens are effective and well tolerated. The study is sponsored by Pfizer Inc. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

37

Pronzato, Paolo, Giorgio Mustacchi, Daniele Giulio Generali, and Alberto Bottini. "Complementary role of Ki67 index and 70-gene signature (MammaPrint) high-risk patients in the St Gallen risk group with uncertain chemotherapy suggestion." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 579. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.579.

Full text

Abstract:

579 Background: St Gallen (SG) Consensus Panel on adjuvant treatment recommends the use of proliferation markers and multigene assays when choosing the appropriate treatment in addition to traditional parameters. Ki67 predictive/prognostic value is widely accepted; we tested its role in increasing the accuracy of risk prediction among Mammaprint (MP) /High(HR) or /Low Risk (LR) breast cancer patients with a SG risk uncertain for chemotherapy selection. Methods: MP was determined (courtesy of Agendia, Amsterdam) in 3 Italian Hospitals on 305 consecutive samples of breast cancer patients. We focused on SG “Intermediate Risk” Group (HER2 neg, no VI and: ER>10<50%, or G2 or Ki67 >15<30% or N1a or T>2<5cm), where the indication for adjuvant CHT still remains uncertain. In MP/HR cases, a “low” Ki67 value (<15%) was used to eliminate CHT suggestion and viceversa an “intermediate” Ki67 value (>15<30%) in MP/LR cases. Results: Overall, 72/305 pts (26.6%) were in SG intermediate risk group with a median age of 64 years (26-98). Ki67 was non available in 4.1% of cases, MP rejected in 16.6%, HR was detected in 39 (54.2%), whereas LR in 21 (29.2%). Ki67 resulted low in 23 MP/HR cases (59%), intermediate in 6 MP/LR cases (28.5%) and in 3 out 12 MP/Rejected cases (25%). The overall concordance between MP and Ki67 was 28/57 (49.1%), MP rejected excluded. Overall MP suggested 39/60 CHT (65%), Ki67 29/69 (42%). Conclusions: The risk of relapse is a continous variable and MP evaluates it in a dichotomy (low vs high) wich could decrease the accuracy of the test. In the selected SG Group, the average risk of 5 yr relapse is around 20% (EBCTCG, Lancet 2011) and MP HR cases in our experience account for 55%. A low Ki67 value could help avoid more than 20% of cytotoxic treatments suggested by MP. In the same way, according to an ER value <50% (2 cases), an intermediate Ki67 value could suggest a more aggressive treatment in a further 13% of cases MP LR (6/21) or Rejected (3/12). MP probably overestimates the risk in 20% of cases and underestimates it in further 20%. Ki67 could be usefull for a more personalized treatment in patients where the indication for adjuvant chemotherapy added to endocrine treatment is uncertain.

APA, Harvard, Vancouver, ISO, and other styles

38

Guralnick, R. M., and G. R. Robinson. "Addendum to paper “On the commuting probability in finite groups” by R.M. Guralnick and G.R. Robinson [J. Algebra 300 (2) (2006) 509–528]." Journal of Algebra 319, no. 4 (February 2008): 1822. http://dx.doi.org/10.1016/j.jalgebra.2007.06.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Panswad, Thongchai, and Somkid Wongchaisuwan. "Mechanisms of Dye Wastewater Colour Removal by Magnesium Carbonate-Hydrated Basic." Water Science and Technology 18, no. 3 (March 1, 1986): 139–44. http://dx.doi.org/10.2166/wst.1986.0045.

Full text

Abstract:

The effects of alkaline magnesium carbonate-hydrated basic as a coagulant, have been investigated in colour reduction experiments using Jar Test apparatus. The raw wastewater was synthetic containing 300 mg/dm3 reactive red dye 519. It has been found that no single flocculant (Mg(OH)2, Ca(OH)2 or CaCO3) can satisfactorily effect colour removal. The effective colour reduction achieved using alkaline magnesium carbonate-hydrated basic has been attributed to the synergistic sorbing capacity of the flocculants Mg(OH)2 and CaCO3.

APA, Harvard, Vancouver, ISO, and other styles

40

Richters, Lisa Katharina Katharina, Oleg Gluz, Nana Weber-Lassalle, Matthias Christgen, Heinz Haverkamp, Sherko Kuemmel, Mohamad Kayali, et al. "Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242)." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 579. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.579.

Full text

Abstract:

579 Background: The phase II trial WSG-ADAPT TN randomized triple-negative breast cancer (TNBC) patients to receive 12 weeks of neoadjuvant nab-paclitaxel (nab-pac) combined with carboplatin (carbo) vs gemcitabine (gem) and showed a substantial improvement of pathological complete response (pCR: ypT0/is, ypN0) with carbo (45.9% vs 28.7%). pCR had a strong favorable impact on iDFS after 3-year follow-up. Distribution of tumor mutations in BC-associated genes and impact of BRCA mutation status on pCR and outcome are analyzed here. Methods: NGS-based mutational analysis of BRCA1/2 and 18 further (potentially) BC-associated genes was performed on DNA derived from pretreatment FFPE samples (gem: n = 158, carbo: n = 108) using a customized gene panel. Variants with a variant fraction of ≥5% were included and classified according to IARC and ENIGMA guidelines. Results: In 42 of the 266 analyzed samples, at least one deleterious BRCA1/2-variant was found (15.8%; BRCA1 n = 37, BRCA2 n = 3, BRCA1+ BRCA2 n = 2) one of which displayed an additional STK11-mutation. In the BRCA1/2-negative cohort, a mutation in one of 14 further analyzed (potential) BC-risk genes was found in 19 samples (7.1%; BARD1 n = 3, CHEK2 n = 2, CDH1 n = 2, FANCM n = 3, PALB2 n = 5, RAD50 n = 1, RAD51C n = 1, RAD51D n = 1, XRCC2 n = 1; no deleterious mutations were found in ATM, BRIP1, MRE11A, NBN). At least one deleterious variant in TP53, PIK3CA, PTEN or MAP3K1 was seen in 89.1% (n = 237; TP53 n = 233, PIK3CA n = 22 PTEN n = 15, MAP3K1 n = 1). In 22 samples (8.3%) no deleterious mutation was identified in the analyzed genes. Overall, patients with tumor BRCA mutation (carbo n = 14, gem n = 28) had 45.2% vs 34.4% pCR (OR = 1.58, 95%-CI: 0.81-3.07, p =.18) without a mutation. pCR in the small group with mutation receiving carbo (n = 14) was 64.3% vs. 34.5% in all others (OR = 3.41, 95%-CI: 1.11-10.50; p =.03); direct comparison to BRCA-positive patients receiving gem (n = 28, 35.7%, OR = 3.2, 95%-CI: 0.85-12.36, p = 0.079) did not reach statistical significance. The results suggest that the strong favorable impact of pCR on iDFS is preserved even among BRCA-positive patients (n = 42, p =.07), as well as in the BRCA-negative subgroup (p <.001). No evidence for a predictive impact of BRCA mutation on efficacy of 4xEC additional chemotherapy was seen overall or within pCR subgroups. Conclusions: Twelve weeks of neoadjuvant nab-pac/carbo is a highly effective anthracycline-free regimen that leads to an excellent pCR-rate of 64% in tumor BRCA1/2-mutated cases. BRC A1/2 mutation status could support this de-escalation strategy in early TNBC, but further prospective validation of survival impacts in larger cohorts and with longer follow up is needed. More detailed survival analyses will be presented at the meeting. Clinical trial information: NCT01815242.

APA, Harvard, Vancouver, ISO, and other styles

41

Giordano, Federica, Stefania Lenna, Riccardo Rampado, Gherardo Baudo, Matteo Massaro, Ashley Rivera, Enrica De Rosa, Jason T. Yustein, and Francesca Taraballi. "Abstract 307: Ponatinib loaded leukocyte-based nanoparticles: A new platform for treating osteosarcoma." Cancer Research 82, no. 12_Supplement (June 15, 2022): 307. http://dx.doi.org/10.1158/1538-7445.am2022-307.

Full text

Abstract:

Abstract The introduction of targeted anticancer drugs has revolutionized treatment. Multi-tyrosine kinase inhibitors (TKIs) are potential therapeutics targeting specific signaling pathways that contribute to cancer progression, including sarcomas. Osteosarcoma is the most common pediatric tumor with a worldwide incidence of 3.4 cases/million annually but without effective treatment. Of the TKIs, Ponatinib demonstrated potent anti-tumor activity; however, it received an FDA black box warning for potential side effects. New treatment and delivery systems must be identified to use Ponatinib clinically. Our laboratory developed novel biomimetic nanoparticles (NPs) synthesized from activated leukocytes called Leukosomes. Leukosomes maintain leukocyte tropism towards inflamed endothelium and can encapsulate and effectively release Ponatinib. We aimed to validate Leukosome technology’s therapeutic potential to specifically target and inhibit primary murine osteosarcoma growth and reduce detrimental side effects. In a 3D sarcosphere model, we observed effective penetration and internalization of NPs in both murine (RF379, 577) and human patient derived xenograft (PDX94, PDX202) osteosarcoma cell lines. Leukosome exhibited 20% increased targeting versus control liposomes. Cell viability decreased 20% after treatment with Ponatinib IC50. Leukosome-Ponatinib IC50 also induced complete inhibition of murine sarcosphere formation and ~60-80% reduction of cell viability. We developed an osteosarcoma orthotopic mouse model by intratibial injection of murine F420 osteosarcoma cells. After 3 weeks, tumor was detected and the mice were injected with Ponatinib NPs. Leukosome showed increased tumor targeting and penetration 1 and 3 hours post-NP injection. Intravenous tail injection of Ponatinib was lethal due to drug-related toxic effects, while intraperitoneal injection of Ponatinib was well tolerated. Conversely, intravenous injection of Ponatinib-loaded NPs did not show toxic effects. In vivo efficacy studies demonstrated that 3 weeks of Ponatinib treatment (2 treatments/week) inhibited tumor growth and increased survival. Similar results were also observed after Leukosome Ponatinib treatment, despite 10 times less Ponatinib in NPs than in free drug. Overall, these results show that leukocyte-derived membrane proteins enhance the accumulation of Ponatinib at the tumor site and surrounding inflamed tissue. While limited Ponatinib encapsulation in NPs remains an open challenge, this formulation underlies the possibility of reducing drug dosage and side effects. Thus, suggest Leukosome’s translational potential as a new targeted drug delivery approach with better outcomes and fewer complications for osteosarcoma patients. Citation Format: Federica Giordano, Stefania Lenna, Riccardo Rampado, Gherardo Baudo, Matteo Massaro, Ashley Rivera, Enrica De Rosa, Jason T. Yustein, Francesca Taraballi. Ponatinib loaded leukocyte-based nanoparticles: A new platform for treating osteosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 307.

APA, Harvard, Vancouver, ISO, and other styles

42

Wang, W., T. Zhang, L. Wang, and H. Song. "FRI0472 DIAGNOSIS AND MANAGEMENT OF ADENOSINE DEAMINASE 2 DEFICIENCY CHILDREN: THE EXPERIENCE FROM CHINA." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 833.1–833. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3481.

Full text

Abstract:

Background:Adenosine deaminase 2 deficiency (DADA2) is a rare antoinflammatory disease caused by mutations in ADA2 gene, few Chinese cases have been reported.Objectives:To describe and compare the clinical features, genotypes, and treatments of Chinese DADA2 patients and foreign cases.Methods:Primary immunodeficiency disease Panel or Whole Exome Sequencing was performed to suspected subjects, and assays for adenosine deaminase 2(ADA2) enzyme activity were also carried out to them and their parents. Case reports of Chinese and foreign patients with DADA2 were searched from PubMed and Chinese domestic databases.Results:Seven unrelated DADA2 children from China were included in our study, 5 were identified at Peking union medical college hospital and 2 had been reported previously (1 on PubMed and 1 in Chinese literatures). 14 mutations in ADA2 were identified, and 9 of which have not been found in other countries. Four children receiving enzymatic analysis had lower ADA2 enzyme activity compared to their parents. Phenotypic manifestations included fever, skin symptoms, vasculitis, neurologic involvement, et al. The treatments varying from steroids, immunosuppressants, and tocilizumab, anti-TNF therapy and hematopoietic stem cell transplantation (HSCT) were effective depending on different phenotype and severity.Conclusion:This study includes the biggest number of Chinese DADA2 patients at present. We recommend combination of enzymatic analysis with gene screening to confirm the diagnosis. Genotypes of patients from China were some different, the clinical manifestations were similar. We suggest anti-TNF therapy may not be necessary for mild case and HSCT should be considered even without hematological phenotype.References:[1]Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370:911-920.[2]Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin Immunol. 2018;38:569-578.[3]Wang XN, Zhou ZX, Li SN, Lai JM, Su GX, Kang M, et al. A case report of DADA2. Chin J Rheumatol. 2019;23:476-478.[4]Liu L, Wang W, Wang Y, Hou J, Ying W, Hui X, et al. A Chinese DADA2 patient: report of two novel mutations and successful HSCT. Immunogenetics. 2019;71:299-305.Disclosure of Interests:None declared

APA, Harvard, Vancouver, ISO, and other styles

43

Rathkopf, Dana E., Michael J. Morris, Daniel Costin Danila, Susan F. Slovin, Jill Elise Steinbrecher, Gabrielle Arauz, Tracy Curley, et al. "A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 4548. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4548.

Full text

Abstract:

4548 Background: ARN-509 is a novel small molecule AR antagonist that impairs AR nuclear translocation and binding to DNA, inhibiting tumor growth and promoting apoptosis, with no partial agonist activity. (Clegg et al., 2012) We conducted a phase I trial to assess safety, pharmacokinetics (PK), and determine the recommended phase II dose (RP2D). Methods: Eligible patients with mCRPC received ARN-509 orally on a continuous daily dosing schedule. Seven doses (30, 60, 90, 120, 180, 240, and 300 mg) were tested using standard 3x3 dose escalation criteria. Once drug concentrations were achieved that met or exceeded optimal levels predicted preclinically, an additional 2 dose levels were tested to further confirm the safety margin of ARN-509 (390 and 480 mg). Anti-tumor activity was assessed by PSA, radiographic responses, and FDHT-PET imaging. Results: Thirty patients were enrolled. The most common grades 1-2 treatment-related adverse events were fatigue (38%), nausea (29%), and pain (24%). There was only 1 treatment-related grade 3 adverse event (abdominal pain) at 300 mg, possibly related to a higher pill burden. PK was shown to be linear and dose-dependent. At 12 weeks, 42% of patients have had ≥ 50% PSA declines. Eleven (37%) patients have discontinued the study due to progression, with the longest patient still on study for more than 16 months. FDHT-PET imaging demonstrated AR blockade at 4 weeks across multiple dose levels. Conclusions: In this phase I study, ARN-509 was shown to be safe and well tolerated with linear PK. Based on promising activity across all dose levels and pharmacodynamic evidence of AR antagonism, an optimal biologic dose of 240 mg daily was selected for phase II investigation. DOD/PCF PCCTC trial sponsored by Aragon Pharmaceuticals.

APA, Harvard, Vancouver, ISO, and other styles

44

Mittra, Joy, Geogy Jiju Abraham, Manoj Kesaria, Sumit Bahl, Aman Gupta, Sonnada M. Shivaprasad, Chebolu Subrahmanya Viswanadham, Ulhas Digambar Kulkarni, and Gautam Kumar Dey. "Role of Substrate Temperature in the Pulsed Laser Deposition of Zirconium Oxide Thin Film." Materials Science Forum 710 (January 2012): 757–61. http://dx.doi.org/10.4028/www.scientific.net/msf.710.757.

Full text

Abstract:

Thin films of zirconium oxide have been deposited using pulsed laser deposition on Zr-base alloy substrates, held at 300 K, 573 K and 873 K, in order to understand the effect of substrate temperature on the deposited film. In this study, a KrF excimer laser having 30 ns pulse width and 600 mJ energy at source has been used for depositing the films from a sintered ZrO2 target using a laser fluence of 5 J.cm-2. After visual observation, deposited thin films were examined using Raman Spectroscopy (RS) and X-ray Photo-electron Spectroscopy (XPS). It has been found that the oxide deposited at 300 K temperature does not show good adherence with the substrate. The oxide films deposited at 573 K and 873 K are found to be adherent with the substrate and lustrous black in appearance. Thin films of zirconia, deposited using pulsed laser on the Zr-base metallic substrate are initially in amorphous state and possibly little deficient in oxygen. The substrate temperature and the duration of holding at high temperature are responsible for the evolution of nanocrystals in the deposited thin films. The stoichiometry of the amorphous oxide film supports its crystallization, below 573 K, into monoclinic and tetragonal phases and not into cubic phase.

APA, Harvard, Vancouver, ISO, and other styles

45

Grijalba-Bendeck, Marcela, Jorge Paramo, and Matthias Wolff. "Catch composition of deep-sea resources of commercial importance in the Colombian Caribbean." Revista de Biología Marina y Oceanografía 54, no. 2 (September 13, 2019): 194. http://dx.doi.org/10.22370/rbmo.2019.54.2.1891.

Full text

Abstract:

Recent studies in the Colombian Caribbean Sea describe the potential for a new deep-sea crustacean fishery between 200 a 550-m depth. In order to support appropriate management plans for their sustainable utilization, the goal of the present study was to identify the catch composition and to detect general trends in the bathymetric distribution of the main four biological categories (crustaceans, teleostean, chondrichthyes and molluscs), in relation to depth strata. A total catch per unit area of 8,759 ind. km-2 and 226 kg km-2 was reported and the major contribution was supported by teleostean fish (89 species; 62% abundance and 73% of total biomass), dominating the depth stratum 200-300 m, followed by crustaceans (36% and 22%, respectively) for deeper waters (> 500 m). Most important species were the fish Coelorinchus caelorhincus (20.2 ind. km-2; 16.7 kg km-2) and the crustaceans Penaeopsis serrata (579 ind. km-2, 7% of the total abundance) and Pleoticus robustus (12.6 kg km-2, 6% of the total biomass). The information obtained is part of a base line required to describing the potential effects of deep-sea fisheries on the ecosystem and supporting future decisions about use, management and conservation of deep resources for this region.

APA, Harvard, Vancouver, ISO, and other styles

46

Ueno, Takayuki, XiWen Bi, Guangyu Liu, Sung Hoon Sim, Seock-Ah Im, Shintaro Takao, Kun Wang, et al. "International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1)." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 1025. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1025.

Full text

Abstract:

1025 Background: Systemic therapy is the standard care in metastatic breast cancer (BC). However, retrospective studies demonstrated survival benefits of locoregional and systemic (combination) therapy in oligometastatic BC. To clarify it, the Federation of Asian Clinical Oncology conducted an international retrospective cohort study (OLIGO-BC1) (UMIN No.000030047). Methods: Oligometastatic BC patients diagnosed from 2007 to 2012 were registered. “Oligometastases” is defined as low volume metastatic disease with limited number and size of metastatic lesions up to five and not necessarily in the same organ by the ABC guidelines. Overall survival (OS) from the diagnosis of oligometastases was the primary endpoint and compared between combination and systemic therapy using a log-rank test. Assuming the 5-year OS of 50% and 40%, respectively, 698 patients were required to achieve 80% power to detect the superiority of combination therapy, at a two-sided significance level. A multivariable Cox regression model with stratification by country was performed to estimate hazard ratio (HR) for therapy and other risk factors. Results: While 1,262 cases had been registered from February 2018 to May 2019, 1,200 remained for analysis after exclusion of unavailable cases. Among them, 573, 529 and 98 cases were registered from China, Japan and Korea, respectively. Luminal BC was recorded in 526 cases (44%), luminal-HER2 BC in 189 (16%), HER2 BC in 154 (13%), triple-negative BC in 166 (14%) and others in 165 (13%). One oligometastatic BC was found in 578 cases, 2 in 289, 3 in 154, 4 in 102 and 5 in 77. Bone metastases were recorded in 301 cases, visceral metastases in 387, locoregional recurrence in 25, local recurrence in 83 and multiple metastatic sites in 404. Combination therapy was performed in 595 cases and systemic therapy in 404. At median follow-up of 4.9 years, 5-year OS was 59.6% and 41.9%, respectively (p < 0.01). An adjusted HR was 0.61 (95% CI: 0.51, 0.74). Type of systemic therapy, younger age, ECOG performance status 0, stage I BC, non-triple negative subtype, fewer metastatic sites, local recurrence and longer disease-free interval were significantly favorable prognostic factors. Discussions: Oligometastatic BC under some conditions seems to be curable. Taken together with recent molecular targeted therapy, locoregional therapy will be advantageous to conquer it. Conclusions: Combination therapy is a promising strategy for patients with oligometastatic BC.

APA, Harvard, Vancouver, ISO, and other styles

47

Huuskonen, Arto, Maiju Pesonen, and Maarit Hyrkäs. "Liharotuisten sonnien ja hiehojen kasvu- ja teurasominaisuudet." Suomen Maataloustieteellisen Seuran Tiedote, no. 28 (January 31, 2012): 1–7. http://dx.doi.org/10.33354/smst.75461.

Full text

Abstract:

Tutkimuksella haluttiin selvittää liharotuisten nautojen kasvu- ja teurasominaisuuksia. Tutkimusaineistona oli teurastamoilta saatu naudan ruhojen teurasaineisto, johon yhdistettiin ProAgria Maatalouden Laskentakeskuksen kautta saadut rotutiedot. Teurastamoaineistoa oli käytössä HK Agri Oy:ltä ja Snellman Lihanjalostus Oy:ltä vuodesta 2007 lähtien, A-Tuottajat Oy:ltä vuodesta 2008 lähtien ja Saarioinen Lihanjalostus Oy:ltä vuodesta 2010 lähtien. Hiehojen osalta alle 300 ja yli 550 vrk:n ikäiset eläimet jätettiin datasta pois. Vastaavasti sonnien osalta alle 365 ja yli 660 vrk:n ikäiset eläimet jätettiin datasta pois. Tutkimuksessa vertailtavia rotuja olivat aberdeen angus (ab), hereford (hf), li-mousin (li), charolais (ch), simmental (si) ja blonde d’Aquitaine (ba). Eläimen katsottiin edustavan kyseistä rotua, jos sen molemmat vanhemmat olivat ProAgria Maatalouden Laskentakeskuksen aineis-tossa luokiteltu ao. rodun edustajiksi. Näiden rajausten jälkeen tutkimusaineisto sisälsi 21 643 teurastettua liharotuista sonnia ja 8 743 liharotuista teurashiehoa. Roduittain ja sukupuolittain lopullinen aineisto muodostui seuraavasti: ab 4 068 sonnia, 1 692 hiehoa; hf 6 323 sonnia, 2 385 hiehoa; li 4 335 sonnia, 1 951 hiehoa; ch 4 421 sonnia, 1 794 hiehoa; si 2 152 sonnia, 774 hiehoa; ba 344 sonnia, 147 hiehoa. Sonnien kasvatusaika (vrk) ja teuraspaino (kg) muodostuivat roduittain seuraaviksi: ab (571 vrk, 368 kg), hf (572 vrk, 368 kg), li (571 vrk, 391 kg), ch (552 vrk, 413 kg), si (565 vrk, 402 kg) ja ba (570 vrk, 393 kg). Teuraspainojen osalta ainoastaan ab- ja hf-rodun sonnit sekä li- ja ba-sonnit eivät eronneet keskenään tilastollisesti merkitsevästi toisistaan. Kaikkien muiden rotujen välillä ero teuraspainossa oli merkitsevä (p<0.001). Sonnien nettokasvu (g/pv), lihakkuusluokka (EUROP) ja rasvaisuusluokka (EUROP) olivat roduittain seuraavat: ab (619 g/pv, R-, 3,3), hf (618 g/pv, R-, 3,2), li (660 g/pv, U-, 2,2), ch (724 g/pv, R+, 2,2), si (686 g/pv, R, 2,3) ja ba (663 g/pv, U-, 1,8). Nettokasvuissa ab ja hf-rodun sonnit sekä li- ja ba-sonnit eivät eronneet keskenään tilastollisesti merkitsevästi toisistaan, mutta kaikkien muiden rotujen välillä ero oli merkitsevä (p<0.001). Ruhojen lihakkuudessa ei ollut tilastollista merkitsevyyttä ab- ja hf-rotujen välillä; kaikki muut erot olivat tilastollisesti merkitseviä. Ruhojen rasvaisuudessa kaikki rodut erosivat toisistaan tilastollisesti merkitsevästi. Hiehojen keskimääräinen kasvatusaika oli 462 vrk. Teuraspaino (kg), nettokasvu (g/pv), lihakkuusluokka (EUROP) ja rasvaisuusluokka (EUROP) olivat roduittain seuraavat: ab (233 kg, 478 g/pv, O, 3,9), hf (252 kg, 468 g/pv, O, 3,9), li (250 kg, 504 g/pv, R-, 2,9), ch (255 kg, 538 g/pv, R-, 2,9), si (244 kg, 510 g/pv, O+, 3,0) ja ba (252 kg, 500 g/pv, R, 2,3). Teuraspainojen osalta ab- ja hf-rodun hiehot, ba- ja ch-hiehot sekä li- ja ba-hiehot eivät eronneet keskenään tilastollisesti merkitsevästi toi-sistaan, mutta muiden rotujen välillä ero teuraspainossa oli merkitsevä (p<0.001). Nettokasvuerot ba-, li- ja si-rotuisten hiehojen välillä eivät olleet merkitseviä; kaikki muut nettokasvuerot olivat tilastolli-sesti merkitseviä (p<0.001). Ruhojen lihakkuudessa kaikki rodut erosivat toisistaan tilastollisesti merkitsevästi (p<0.001). Ruhojen rasvaisuudessa ei ollut tilastollista merkitsevyyttä ab- ja hf-rotujen eikä ch- ja li-rotujen välillä; kaikki muut erot olivat tilastollisesti merkitseviä (p<0.001).

APA, Harvard, Vancouver, ISO, and other styles

48

Zhevnenko, Sergei, Danil V. Vaganov, and Eugene Gershman. "The Liquid Bismuth Penetration from Solid Bi₂Te₃: Grain Boundary Embrittlement and Effect of Impurities." Defect and Diffusion Forum 309-310 (March 2011): 265–70. http://dx.doi.org/10.4028/www.scientific.net/ddf.309-310.265.

Full text

Abstract:

The liquid bismuth penetration from solid bismuth telluride (Bi2Te3) into grain boundaries of copper and copper-based solid solutions was studied. The experiments were performed at 570 oC in hydrogen atmosphere. The copper specimens were annealed from 10 to 90 minutes. Solid Bi2Te3 didn’t contact with copper specimens during experiments, so copper was covered by the decay products of Bi2Te3 through the gas phase. Liquid Bi penetration leads to grain boundary embrittlement of copper. We assumed that the depth of penetration is equal to the length of cracks which are formed after sample bending. It was shown that there is only bismuth at the grain boundaries while on the surface tellurium also exists. Bismuth concentration in the grain boundaries measured by Auger spectroscopy was about 10-20 at. % and the width of penetration channel was less then 10 nm. Bismuth covered the grain boundaries uniformly. Time dependence of the penetration depth was approximately parabolic. In the present work the effect of impurities (silver, iron) on grain boundary liquid bismuth penetration was studied also. It was shown that silver accelerates the penetration in contrast to iron. The probable reasons were discussed.

APA, Harvard, Vancouver, ISO, and other styles

49

Rathkopf, Dana E., Daniel Costin Danila, Michael J. Morris, Susan F. Slovin, Jill Elise Steinbrecher, Gabrielle Arauz, Peter J. Rix, et al. "Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 43. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.43.

Full text

Abstract:

43 Background: In CRPC, androgen receptor (AR) overexpression is associated with resistance to first-generation anti-androgen therapy such as bicalutamide. ARN-509 is a novel small molecule AR antagonist that impairs AR nuclear translocation and binding to DNA, inhibiting tumor growth and promoting apoptosis, with no partial agonist activity. Preclinical data shows that ARN-509 binds AR with 5-fold greater affinity than bicalutamide, and induces tumor regression in hormone-sensitive and CRPC xenograft models. Methods: In this open-label, Phase 1/2 study, mCRPC patients received ARN-509 orally on a continuous daily dosing schedule. In Phase 1 , 7 doses (30, 60, 90, 120, 180, 240, 300 mg) were tested using standard 3x3 dose escalation criteria to assess safety, PK, and determine the recommended Phase 2 dose (RP2D). Preliminary anti-tumor activity was assessed by PSA kinetics, radiographic responses, circulating tumor cells (CTCs), and FDHT-PET imaging. Results: Twenty-four patients (median age 68 yrs, Gleason Score 8; prior docetaxel 13%) were enrolled. The most common Grade 1-2 treatment-related adverse events were fatigue (38%), nausea (29%), and pain (24%). There was only 1 treatment-related Grade 3 adverse event (abdominal pain) at 300 mg, possibly related to a higher pill burden, which led to an additional 3 patients being enrolled at the highest dose with no further dose limiting toxicities. PK was shown to be linear and dose-dependent. Twelve patients (55%) had ≥ 50% PSA declines. To date, 7 patients have discontinued the study due to progression, with the longest patient still on study for more than 1 year. FDHT-PET imaging demonstrated AR blockade at 4 weeks across multiple dose levels. Based on preclinical assessment of maximum efficacious dose, PK, and promising activity across all doses, 240 mg was selected as the RP2D. Conclusions: In this Phase 1 study, ARN-509 was shown to be safe and well tolerated, with promising preliminary activity based on PSA and pharmacodynamic evidence of AR antagonism. The Phase 2 portion of the study will enroll up to 90 patients with treatment-naïve non-metastatic and mCRPC.

APA, Harvard, Vancouver, ISO, and other styles

50

Galstyan, Irina A., Nelya A. Metlyaeva, Mikhail V. Konchalovsky, Vladimir Yu Nugis, Olga V. Shcherbatykh, Lyubov A. Yunanova, Felix S. Torubarov, and Zoya F. Zvereva. ""Subacute" course of chronic radiation syndrome." Russian Journal of Occupational Health and Industrial Ecology 61, no. 9 (October 20, 2021): 572–79. http://dx.doi.org/10.31089/1026-9428-2021-61-9-572-579.

Full text

Abstract:

Introduction. The use of ionizing radiation as a production factor in the late 1940s - early 1950s. began in the absence of a clear understanding of the permissible radiation doses for workers, as well as knowledge of diagnostic criteria and developed therapeutic measures for developing chronic radiation sickness (CRS). Since then, a great deal of experience has been accumulated in the diagnosis and treatment of CRS. Currently, there are no conditions at the workplace for chronic exposure of workers in doses exceeding the permissible ones. However, taking into account the constant expansion of the scope of using sources of ionizing radiation, it is necessary to remember about the possibility of CRS development due to prolonged exposure in case of violation of their storage or their loss. The study aimed to explore the formation of radiation bone marrow syndrome (RBS) due to chronic exposure in doses that exceed the maximum permissible, accumulated with different dose rates of radiation. Material and methods. We selected the medical records of 27 people (24 men and 3 women) who had RBS as a result of chronic professional gamma radiation exposure. The selection criteria were the diagnosis of grade II-III chronic radiation syndrome (CRS) in the presence of agranulocytosis or anemic syndrome in the period of the disease formation and, especially, in the development of myelodysplastic syndrome (MDS) or aplastic anemia in the period of the CRS consequences. Identified clinical and dosimetric CRS features of 27 patients exposed to chronic irradiation with a dose rate of 0.0002-0,009 Gy/h and the summary dose of 1.7 and 9.6 Gy, accumulated over a period of 6 to 96 months were compared the characteristics of 84 patients CRS exposed a lower dose rates (less than 0,0003 Gy/h) and 26 patients with acute radiation syndrome moderate (II) severity as a result of irradiation the dose rates of 0.14-3,7 Gy/h, total dose of 2 to 4 Gy. Results. The criteria of atypical subacute CRS course are identified: the rate of chronic radiation exposure - not less than 0.001-0.009 Gy/h with a summary dose of 1.7-9.6 Gy accumulated over a period of 6-96 months, the presence of agranulocytosis in the period of CRS formation and anemic syndrome in the periods of CRS formation and outcomes. These signs predict the development MDS in 60% of the patients in the period of the CRS consequences. Conclusion. Retrospective study determined that long-term human exposure to a dose rate of 0.001-0,009 Gy/h (0,005-0,05 Gy/day) and more in the accumulation of a summary dose of 1.7 and 9.6 Gy and duration of contact 6-96 months in 60% of cases can be expected development CRS with a subacute clinical course RBS. The main factor determining this feature of the course of RBS is the dose rate exceeding 0.001 Gy / h (2 Gy/year). In the subacute course of CRS, the early outcome in MDS is essentially deterministic. The development of agranulocytosis and anemic syndrome are typical signs of the subacute course of CRS.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic '579.307 2'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles